antibody, pharmaceutical composition, pharmaceutical combination and uses of an antibody, a pharmace

专利摘要:
PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMBINATION AND METHOD FOR THE TREATMENT AND/OR PREVENTION OF A CANCER AND ANTIBODY. IN ACCORDANCE WITH THE PRESENT INVENTION, A CANCER ANTIGEN PROTEIN WHICH IS SPECIFICALLY EXPRESSED ON CANCER CELL SURFACES HAS BEEN IDENTIFIED AND THEREFORE THE USE OF ANTIBODY DIRECTED AGAINST CANCER PROTEIN IS PROVIDED. SPECIFICALLY, THE PRESENT INVENTION PROVIDES A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF A CANCER, WHICH COMPRISES AN ANTIBODY COMPRISING A HEAVY CHAIN VARIABLE REGION COMPRISING THE SEQ ID NOS: 39, 40 AND 41 AND A LIGHT REGION THAT COMPRISES SEQ ID NOS: 43, 44 AND 45 OR A FRAGMENT THEREOF AS AN ACTIVE INGREDIENT AND POSSESSING IMMUNOLOGICAL REACTIVITY WITH A CAPRIN-1 PROTEIN.
公开号:BR112012019098B1
申请号:R112012019098-9
申请日:2011-02-04
公开日:2021-07-06
发明作者:Fumiyoshi Okano；Takanori Saito
申请人:Toray Industries, Inc.；
IPC主号:

专利说明:

[001] The present invention relates to a new pharmaceutical use of an antibody against CAPRIN-1 or fragment thereof, as an agent to treat and/or prevent a cancer. BACKGROUND OF THE INVENTION
[002] Cancer is the leading cause of death. The therapy currently performed mainly comprises surgical therapy in combination with radiotherapy and chemotherapy. Despite the development of new surgical procedures and the discovery of new anticancer agents in recent years, with the exception of some types of cancers, the results of treating it have not improved. Recent advances in molecular biology or cancer immunology have led to the identification of antibodies that specifically react with cancer, cancer antigens that are recognized by cytotoxic T cells, genes encoding cancer antigens, and the like. Demand for specific therapies targeted against cancer antigens is increasing (non-patent literature 1).
[003] In cancer therapy, it is desirable that peptides, polypeptides or proteins recognized as antigens are almost absent in normal cells, but present specifically in cancer cells, in order to alleviate side effects. In 1991, Boon, et al. (Ludwig Institute for Cancer Research in Belgium) isolated a MAGE1 human melanoma antigen recognized by CD8-positive T cells by a cDNA expression cloning method using an autologous cancer cell line and cancer-reactive T cells (Non Literature patent 2). Subsequently, the SEREX method (serological identification of antigens by recombinant expression cloning) was described, which comprised the identification of tumor antigens recognized by antibodies that are produced in vivo in response to autologous cancer of a patient's own cancer by a cloning technique of gene expression (Non-patent Literature 3 and Patent Literature 1). Using this method, some cancer antigens, which are almost never expressed on normal cells, but which are specifically expressed on cancer cells, have been isolated (Non-Patent Literatures 4-9). In addition, clinical trials based on cell therapies directed against some cancer antigens using immune cells specifically reactive to cancer antigens or cancer-specific immunotherapies with vaccines or the like containing cancer antigens have been carried out.
[004] On the other hand, in recent years, several antibody drugs that target antigenic proteins on cancer cells for cancer treatment have emerged around the world. Antibody drugs exhibit some pharmacological effects as cancer-specific therapeutic agents and thus attract attention. However, most of the antigen proteins used as a target for the antibody are also expressed on normal cells, so that not only cancer cells but also normal cells expressing such antigens are damaged as a result of the administration of the antibodies. The resulting side effects are cause for concern. Therefore, it is expected that identifying cancer antigens that are specifically expressed on the surface of a cancer cell and using antibodies targeted to cancer antigens as pharmaceuticals will accomplish treatment with antibody drugs with lower side effects.
[005] Cytoplasmic proliferation-associated protein 1 (CAPRIN-1) is expressed when normal cells in the resting phase are activated or subjected to cell division, and it is an intracellular protein known to form intracellular stress granules with RNA within the cells, so as to be involved in mRNA transport and regulation of translation. However, there are many other names that represent CAPRIN-1, such as the GPI-1 anchored membrane protein or membrane component 1 surface marker protein (M11S1), as if such proteins were known to be cell membrane proteins. These names originate from a report that the CAPRIN-1 gene sequence is a membrane protein that has a GPI binding region and is expressed in colorectal cancer cells (Non-patent Literature 10). However, the CAPRIN-1 genetic sequence provided in this report was later revealed to be wrong. Then it was reported that deletion of a single nucleotide in the CAPRIN-1 gene sequence registered in GenBank or similar bank causes a change in the frame, so that 80 amino acids are lost from the C-terminal end, which results in generation of an artifact (74 amino acids), which corresponds to the GPI-binding portion in the previous report, and additionally another error is also present 5' of the gene sequence, so that 53 amino acids were lost from the N-terminal end. (Non-patent Literature 11). It was also recently reported that the protein encoded by the CAPRIN-1 gene sequence registered in GenBank or similar bank is not a cell membrane protein (Non-patent Literature 11).
[006] Furthermore, based on the non-patent literature 10 report that CAPRIN-1 is a cell membrane protein, patent literatures 2 and 3 describe that CAPRIN-1 (as a cell membrane protein) under the name M11S1 can be used as a target of an antibody drug in cancer therapy, although they do not describe practical examples of treatment using an antibody against the protein. However, as reported in non-patent literature 11, it is believed since the deposit of patent literature 2 to date that CAPRIN-1 is not expressed on the surface of a cell. The contents of patent literatures 2 and 3, based only on the incorrect information that CAPRIN-1 is a cell membrane protein, should not be clearly understood as common general knowledge to those skilled in the matter. LITERATURE OF THE STATE OF THE TECHNIQUE PATENTARY LITERATURE
[007] Patent Literature 1: US Patent 5,698,396
[008] Patent Literature 2: US2008/0075722
[009] Patent Literature 3: WO2005/100998. NON-PATENTARY LITERATURE
[010] Non-patent Literature 1: Tsuyoshi Akiyoshi, "Gan To Kagaku-Ryoho (Cancer and Chemotherapy)," 1997, Vol. 24, pp 551-519 (Cancer and Chemotherapy Publishers, Inc., Japan).
[011] Non-Patent Literature 2: Bruggen P. et al., Science, 254:1643-1647 (1991).
[012] Non-Patent Literature 3: Proc. Natl. Academic Sci. USA, 92:11810-11813 (1995).
[013] Non-Patent Literature 4: Int. J. Cancer, 72:965-971 (1997).
[014] Non-Patent Literature 5: Cancer Res., 58:1034-1041 (1998).
[015] Non-Patent Literature 6: Int. J. Cancer, 29:652-658 (1998).
[016] Non-Patent Literature 7: Int. J. Oncol., 14:703-708 (1999).
[017] Non-Patent Literature 8: Cancer Res., 56:4766-4772 (1996).
[018] Non-Patent Literature 9: Hum. Mol. Genet 33-39, 1997.
[019] Non-Patent Literature 10: J. Biol Chem., 270:20717-20723, 1995.
[020] Non-Patent Literature 11: J. Immunol., 172:2389-2400, 2004. BRIEF DESCRIPTION OF THE INVENTION PROBLEMS TO BE SOLVED BY THE INVENTION
[021] The objects of the present invention are to identify a cancer antigen protein that is specifically expressed on the surface of a cancer cell and to provide the use of an antibody directed against the cancer antigen protein as an agent to treat and/or prevent a cancer. WAYS TO SOLVE PROBLEMS
[022] As a result of intensive studies, the present inventors have now obtained a cDNA encoding a protein that binds to an antibody existing in the serum of dogs with breast cancer by the SEREX method using two cDNA libraries prepared from testis tissues of dog and serum from dogs with breast cancer. The inventors have further prepared CAPRIN-1 proteins having the even numbered amino acid sequences of SEQ ID NOS: 2 to 30 and antibodies against such CAPRIN-1 proteins based on the obtained dog gene and the corresponding homologous genes in human, bovine, horse, mouse, and chicken. Thus, the inventors of the present invention have now revealed that CAPRIN-1 is specifically expressed in breast cancer, brain tumor, leukemia, lymphoma, lung cancer, cervical cancer, bladder cancer, esophageal cancer, colorectal cancer, gastric cancer, and kidney cell cancer, and that a portion of the CAPRIN-1 protein is specifically expressed on the surface of each cancer cell. The inventors have now found that an antibody or antibodies against the portion of CAPRIN-1 expressed on the surface of each cancer cell is/are cytotoxic to cancer cells expressing CAPRIN-1. Based on these findings, the present invention as described below has been completed.
[023] The present invention has the following characteristics.
[024] The present invention provides a pharmaceutical composition for treating and/or preventing a cancer, comprising an antibody comprising a heavy chain variable region comprising SEQ ID NOS: 39, 40 and 41; and a light chain variable region comprising SEQ ID NOS: 43, 44, and 45 or a fragment thereof as an active ingredient that has an immunological reactivity with a CAPRIN-1 protein.
[025] In an example embodiment, the above cancer is breast cancer, brain tumor, leukemia, lymphoma, lung cancer, cervical cancer, bladder cancer, esophageal cancer, colorectal cancer, gastric cancer or kidney cancer .
[026] In another embodiment example, the above antibody is a human antibody, humanized antibody, chimeric antibody, single chain antibody or bispecific antibody.
[027] This description includes part or all of the content as disclosed in the description and/or drawings of Japanese patent application No. 2010-023452, which is a literature of the prior art of the present application. EFFECTS OF THE INVENTION
[028] The antibody against CAPRIN-1 used in the present invention is cytotoxic to cancer cells. Thus, the antibody against CAPRIN-1 is useful to treat or prevent cancers. BRIEF DESCRIPTION OF THE FIGURES
[029] Fig. 1 shows the expression patterns of genes encoding CAPRIN-1 proteins in normal tissues and in tumor cell lines. Reference No. 1 indicates the expression patterns of genes encoding CAPRIN-1 proteins, and Reference No. 2 indicates the expression patterns of GAPDH genes.
[030] Fig. 2 shows the cytotoxicity of an anti-CAPRIN-1 #1 monoclonal antibody (which is reactive with cancer cell surfaces) against the breast cancer cell line MDA-MB-157 expressing CAPRIN- 1. Reference No. 3 indicates the activity exhibited when anti-CAPRIN-1 #1 monoclonal antibody was added. Reference No. 4 indicates the activity exhibited when PBS was added in place of the antibodies.
[031] Fig. 3 shows the anti-tumor effects of anti-CAPRIN-1 #1 monoclonal antibody (which is reactive with the surface of cancer cells) against Balb/c mice in which the mouse breast cancer cell line 4T1 expressing CAPRIN-1 was transplanted. Reference No. 5 indicates the tumor size of a mouse to which the monoclonal antibody anti-CAPRIN-1 #1 was administered. Reference No. 6 indicates the tumor size of a mouse given PBS in place of the antibodies. DETAILED DESCRIPTION OF THE PRESENT INVENTION
[032] The antitumor activity of an antibody against a polypeptide represented by any of the even numbered sequences of SEQ ID NOS: 2 to 30 used in the present invention can be evaluated by examining the suppression of tumor growth in vivo, in animals with cancer , or, by assessing whether the antibody exhibits cytotoxicity via immune cells or complement to tumor cells expressing the polypeptide in vitro, as described further below.
[033] In context, the nucleotide sequences of protein coding polynucleotides comprising the even numbered amino acid sequences (i.e., SEQ ID NOS: 2, 4, 6, ..., 28, 30) of SEQ ID NOS: 2 to 30 are represented by the odd numbered sequences (i.e., SEQ ID NOS: 1, 3, 5, ..., 27, 29) of SEQ ID NOS: 1 to 29.
[034] The amino acid sequences that are represented by SEQ ID NOS: 6, 8, 10, 12 and 14 in the Sequence Listing disclosed in the present invention are the amino acid sequences of CAPRIN-1 isolated as polypeptides that specifically bind to antibodies existing in the serum of a dog with cancer, by the SEREX method using a cDNA library from testicular tissue of a dog and the serum of a dog with breast cancer. The amino acid sequences represented by SEQ ID NOS: 2 and 4 are the amino acid sequences of CAPRIN-1 isolated as human homologs. The amino acid sequence represented by SEQ ID NO: 16 is the amino acid sequence of CAPRIN-1 isolated as a homolog from cattle. The amino acid sequence represented by SEQ ID NO: 18 is the amino acid sequence of CAPRIN-1 isolated as a horse homologue. The amino acid sequences represented by SEQ ID NOS: 20 to 28 are the amino acid sequences of CAPRIN-1 isolated as mouse homologs. The amino acid sequence represented by SEQ ID NO:30 is the amino acid sequence of CAPRIN-1 isolated as a chicken homologue (see Example 1 described below). CAPRIN-1 is known to be expressed when normal, resting cells are activated or trigger cell division.
[035] It was known that CAPRIN-1 was not expressed on cell surfaces. However, as a result of examination by the inventors of the present invention, it has now been revealed that a portion of the CAPRIN-1 protein is expressed on the surfaces of cells of various types of cancer. Thus, it was revealed that an antibody with immunological reactivity with a partial region of a CAPRIN-1 protein that is expressed on the surface of cancer cells or that specifically recognizes the region (i.e., specifically binds to the region) and comprises a a heavy chain variable region comprising SEQ ID NO: 39, 40, and 41 and a light chain variable region comprising SEQ ID NO: 43, 44, and 45 exhibit antitumor activity.
[036] The anti-CAPRIN-1 antibody described above used in the present invention can be any type of monoclonal antibody, as long as it can exhibit antitumor activity. Examples of such an antibody include recombinant antibodies, such as a synthetic antibody, a multispecific antibody, a humanized antibody, a chimeric antibody, and a single chain antibody (scFv), a human antibody, and fragments of these antibodies, such as Fab, F( ab')2, and Fv. These antibodies and fragments thereof can be prepared by methods known to those skilled in the art. Furthermore, when a subject is a human, human antibodies or humanized antibodies are desired in order to prevent or suppress rejection.
[037] The term "specifically binds to a partial region of a CAPRIN-1 protein", as used herein, means that "the antibody specifically binds to a specific region of a CAPRIN-1 protein without substantially binding to others portions of the protein that are not such region”.
[038] The antitumor activity of an antibody that can be used in the present invention can be evaluated, as described below by in vivo analysis of tumor growth suppression in animals with cancer, or by evaluating whether or not said antibody exhibits an activity of in vitro cytotoxicity, which is mediated by immune or complement, in tumor cells expressing the polypeptide.
[039] Furthermore, examples of subject to treat and/or prevent a cancer of the present invention, include mammals, such as humans, pets, domestic animals and animals for competition. A preferred subject is a human.
[040] The preparation of antigens, antibodies and pharmaceutical compositions related to the present invention are described below. ANTIGEN PREPARATION FOR ANTIBODY PREPARATION
[041] The proteins or fragments thereof to be used as sensitizing antigens to obtain the anti-CAPRIN-1 antibodies used in the present invention can be derived from any animal species, without particular limitation, such as humans, dogs, cattle, horses, mice, rats, and chickens. However, proteins or fragments thereof are preferably selected with regard to compatibility with the parent cells used for cell fusion. In general, mammalian-derived proteins are preferred, and in particular, human-derived proteins are preferred. For example, when CAPRIN-1 is human CAPRIN-1, they can be used; human CAPRIN-1 protein, a peptide partial thereof, or cells expressing human CAPRIN-1.
[042] The nucleotide sequences and amino acid sequences of human CAPRIN-1 and homologues thereof can be obtained by accessing GenBank (NCBI, USA) and using an algorithm such as BLAST or FASTA (Karlin and Altschul, Proc. Natl. Acad. Sci USA, 90:5873-5877 1993; Altschul et al, Nucleic Acids Res, 25:3389-3402, 1997).
[043] In the present invention, based on the nucleotide sequence (SEQ ID NO: 1 or 3), or the amino acid sequence (SEQ ID NO: 2 or 4) of human CAPRIN-1, a target nucleic acid or target protein comprises a sequence from about 70% to 100%, preferably from 80% to 100%, more preferably from 90% to 100%, even more preferably from 95% to 100% (e.g. 97% to 100%, 98% at 100%, 99% to 100%, or 99.5% to 100%) sequence identity with the nucleotide sequence or amino acid sequence of the ORF or mature portion of human CAPRIN-1. As used herein, the term "% sequence identity" refers to a percentage (%) of identical amino acids (or nucleotides) relative to the total number of amino acids (or nucleotides) when two sequences are aligned to achieve the largest similarity with or without the introduction of gaps.
[044] The length of a CAPRIN-1 protein fragment varies from the amino acid length of an epitope (antigenic determinant), which is the minimum unit recognized by an antibody, to a length less than the total length of the protein. The term "epitope" refers to a polypeptide fragment that has antigenicity or immunogenicity in mammals, preferably in humans, and the minimum unit of the epitope consists of about 7 to 12 amino acids (for example, 8 to 11 amino acids) .
[045] Polypeptides comprising the human CAPRIN-1 protein or the protein partial peptides mentioned above can be synthesized by a chemical synthesis method, such as the Fmoc method (fluorenylmethyloxycarbonyl method) or the tBoc method (t-butyloxycarbonyl method) ( Edited by the Japanese Society of Biochemistry, Seikagaku Jikken Koza (Biochemical Experimental Lecture Series) 1, Protein Chemistry IV, Chemical Modification and Peptide Synthesis, TOKYO KAGAKU DOZIN (Japan), 1981). Alternatively, the polypeptides mentioned above can also be synthesized by conventional methods using various commercially available peptide synthesizers. Furthermore, using known genetic engineering techniques (eg, Sambrook et al., Molecular Cloning, 2nd Edition, Current Protocols in Molecular Biology (1989), Cold Spring Harbor Laboratory Press, Ausubel et al., Short Protocols in Molecular Biology, 3rd Edition, A Compendium of Methods from Current Protocols in Molecular Biology (1995), John Wiley & Sons), a polynucleotide encoding the above polypeptide is prepared and then incorporated into an expression vector, which is subsequently introduced into a host cell in order to produce a polypeptide of interest in the host cell, and then recovering this polypeptide.
[046] The polynucleotides encoding the above polypeptides can be easily prepared by known techniques of genetic engineering or by conventional techniques using a commercially available nucleic acid synthesizer. For example, DNA comprising the nucleotide sequence of SEQ ID NO: 1 can be prepared by PCR, using a human chromosomal DNA or cDNA library as a template, and a pair of primers designed to be able to amplify the sequence of nucleotides represented by SEQ ID NO: 1. PCR conditions can be properly determined. For example, PCR conditions comprise performing 30 cycles of the reaction cycle: denaturation at 94°C for 30 seconds; annealing at 55 °C for 30 seconds to 1 minute, and extension at 72 °C for 2 minutes, using a thermostable DNA polymerase (eg, Taq polymerase or Pfu-polymerase) and PCR buffer containing Mg2+, followed by the reaction at 72 °C for 7 minutes. However, the PCR conditions are not limited to the example above. PCR techniques, conditions, etc., are described in Ausubel et al., Short Protocols in Molecular Biology, 3rd Edition, A Compendium of Methods from Current Protocols in Molecular Biology (1995), John Wiley & Sons (especially Chapter 15 ).
[047] Furthermore, based on the nucleotide sequence and amino acid sequence information represented by SEQ ID NOS: 1 to 30 in the Sequence Listing described in the present invention, appropriate probes or primers are prepared and then a library cDNA from a human or the like is screened using them so that the desired DNA can be isolated. A cDNA library is preferably constructed from cells, organs or tissues expressing proteins having the even numbered sequences of SEQ ID NOS: 2 to 30. Examples of such cells or tissues include testis derived cells or tissues, cancers or tumors, such as leukemia, breast cancer, lymphomas, brain tumors, lung cancer, colorectal cancer, and the like. Procedures such as preparation of probes or primers, construction of a cDNA library, screening of a cDNA library and cloning of target genes are known to a person skilled in the art and such procedures can be carried out by the methods described. in Sambrook et al. Molecular Cloning, 2nd Edition, Current Protocols in Molecular Biology (1989), Ausbel et al., (above), and etc. The DNA encoding the human CAPRIN-1 protein or a partial peptide thereof can be obtained from the DNA thus obtained.
[048] Host cells can be of any cell type, as long as they can express the above-mentioned polypeptide. Examples of prokaryotic cells include, but are not limited to, E. coli and the like. Examples of eukaryotic cells include, but are not limited to, mammalian cells, such as monkey kidney cells (COS1) and Chinese hamster ovary (CHO) cells, the human fetal kidney cell line (HEK293), lineage from mouse fetal skin cells (NIH3T3), yeast cells such as budding yeast and yeast, silkworm cells, and Xenopus oocytes.
[049] When prokaryotic cells are used as host cells, an expression vector used in the present invention includes a replicable origin within prokaryotic cells, a promoter, a ribosome binding site, a multiple cloning site, a terminator, a drug resistance gene, a complementary auxotrophic gene, and so on. Examples of expression vectors for Escherichia coli include a pUC-based vector, pBluescript II, a pET expression system, and a pGEX expression system. DNA encoding the above polypeptide is incorporated into such an expression vector, the prokaryotic host cells are transformed with the vector, the transformed cells thus obtained are cultured, and thereby the polypeptide encoded by the DNA can be expressed in prokaryotic host cells. At this time, the polypeptide can also be expressed as a fusion protein with another protein.
[050] When eukaryotic cells are used as host cells, an expression vector used in the present invention is an expression vector for eukaryotic cells, which contains a promoter, a splicing region, a poly(A) addition site, and similar. Examples of such expression vectors include pKa1, pCDM8, pSVK3, pMSG, pSVL, pBK-CMV, pBK-RSV, EBV vector, pRS, pcDNA3, and pYES2. In a similar manner as described above, the DNA encoding the above polypeptide is incorporated into such an expression vector, the eukaryotic host cells are transformed with the vector, the transformed cells thus obtained are cultured, and thus the polypeptide encoded by DNA can be expressed in eukaryotic host cells. When pIND/V5-His, pFLAG-CMV-2, pEGFP-N1, pEGFP-C1 or similar is used as an expression vector, the above polypeptide can be expressed as a fusion protein to which a tag), such as the His tag (e.g. (His)6-(His)10), FLAG tag, myc tag, HA tag or GFP, was added.
[051] For the introduction of an expression vector into host cells, a known method can be employed, such as electroporation, the calcium phosphate method, the liposome method, DEAE dextran method, microinjection, viral infection, lipofection , and binding to a cell membrane permeable peptide.
[052] The polypeptide of interest can be isolated and purified from host cells by a combination of known separation processes. Examples of such known separation processes include, but are not limited to, treating with a denaturing agent such as urea or a surfactant; ultrasonication; enzymatic digestion; salting-out or fractionation and solvent precipitation; dialysis; centrifugation; ultrafiltration; gel filtration; SDS-PAGE; isoelectric focusing; ion exchange chromatography; hydrophobic interaction chromatography, affinity chromatography and reverse phase chromatography. ANTIBODY STRUCTURE
[053] An antibody is a heteromultimeric glycoprotein that generally contains at least two heavy chains and two light chains. Antibodies that are not of the IgM class are heterotetrameric glycoproteins of about 150-kDa, composed of two identical light (L) chains and two identical heavy (H) chains. Normally, each light chain is connected to a heavy chain through a single covalent disulfide bond, however, the number of disulfide bonds between heavy chains varies among different immunoglobulin isotypes. Each heavy chain or light chain also has an intrachain disulfide bond. Each heavy chain has a variable domain (VH region) at one end followed by several constant regions. Each light chain has a variable domain (VL region), and has a constant region at an end opposite the other end. The constant region of a light chain is aligned with the first constant region of a heavy chain, and a light chain variable domain is aligned with a heavy chain variable domain. The specific region of an antibody variable domain exhibits specific variability which is referred to as the complementarity determining region (CDR) so that it confers binding specificity on the antibody. A portion of a variable region, which is relatively conserved, is referred to as a framework (FR) region (or framework region). The complete heavy chain and light chain variable domains separately contain four FRs linked via three CDRs. The three CDRs of a heavy chain are referred to as CDRH1, CDRH2, and CDRH3, in order from the N-terminal end. Likewise, in the case of a light chain, CDRLs are referred to as CDRL1, CDRL2 and CDRL3. CDRH3 is the most important for the binding specificity of an antibody to an antigen. In addition, the CDRs from each chain are held together in a state adjacent to each other due to the FR regions, contributing to the formation of the antibody's antigen-binding site along with the CDRs from the other chain. The constant region does not directly contribute to the binding of an antibody to an antigen, but it has several effector functions, such as antibody participation in antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis through binding to an FCY receptor, a half-life/clearance rate via the neonatal Fc receptor (FcRn) and complement dependent cytotoxicity (CDC), via a C1q component of the complement system cascade. ANTIBODY PREPARATION
[054] The term "anti-CAPRIN-1 antibody", as used herein, refers to an antibody with immunological reactivity to a full-length CAPRIN-1 protein or a fragment thereof.
[055] As used in the present invention, the term "immunological reaction" refers to the in vivo binding property of an antibody to a CAPRIN-1 antigen. Through such in vivo binding, the tumor-damaging function (eg, death, suppression, or degeneration) is displayed. Specifically, an antibody used in the present invention can be any type of antibody, as long as it binds to a CAPRIN-1 protein so as to be able to damage the tumor, such as a leukemia, lymphoma, breast cancer, brain tumor, lung cancer, bladder cancer, cervical cancer, esophageal cancer, gastric cancer, kidney cancer or colorectal cancer.
[056] In the present invention, examples of an antibody include, but are not particularly limited to, antibodies as long as: a monoclonal antibody, a synthetic antibody, a multispecific antibody, a human antibody, a humanized antibody, a chimeric antibody, a single-chain antibody, and an antibody fragment (for example, Fab and F(ab')2). Furthermore, the antibody can be an immunoglobulin molecule of any class such as IgG, IgE, IgM, IgA, IgD or IgY, or of any subclass such as IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2.
[057] The antibody can be further modified by glycosylation, acetylation, formylation, amidation, phosphorylation, pegylation (PEG) and/or the like.
[058] Examples of the preparation of various monoclonal antibodies are described below.
[059] When the antibody is a monoclonal antibody, for example, the SK-BR-3 breast cancer cell line expressing CAPRIN-1 is administered to a mouse for immunization, the mouse spleen is removed, the cells are separated and then the mouse myeloma cells and cells are fused. Among the fusion cells thus obtained (hybridomas), an antibody producing clone which has the effect of suppressing the proliferation of cancer cells is selected. A hybridoma that produces a monoclonal antibody that has the effect of suppressing the proliferation of cancer cells is isolated, the hybridoma is cultured, and then an antibody is purified from the culture supernatant by general affinity purification, so that the antibody can be prepared.
[060] The hybridoma that produces a monoclonal antibody can also be prepared as described below, for example. First, an animal is immunized with a sensitizing antigen according to a known method. A general method is performed by injecting a sensitizing antigen to a mammal intraperitoneally or subcutaneously. Specifically, a sensitizing antigen is diluted with PBS (phosphate buffered saline), saline, or the like in an appropriate amount, followed by suspension. The resultant is then mixed with a suitable amount of a general adjuvant as needed, such as Freund's complete adjuvant. After emulsification, the solution was administered to a mammal several times every 4 to 21 days. Furthermore, a suitable vehicle can also be used after immunization with a sensitizing antigen.
[061] A mammal is immunized as described above. After confirmation of an increase in the desired serum antibody level, the immunized cells are collected from the mammal and then subjected to cell fusion. Preferred immunized cells are particularly splenocytes.
[062] Mammalian myeloma cells are used as other parental cells to be fused with the immunized cells. As myeloma cells, several known cell lines are preferably employed, such as; P3U1 (P3-X63Ag8U1), P3 (P3x63Ag8.653) (J. Immunol. (1979) 123, 1548-1550), P3x63Ag8U.1 (Current Topics in Microbiology and Immunology (1978) 81, 1-7), NS- 1 (Kohler.G. and Milstein, C.Eur.J.Immunol. (1976) 6, 511-519), MPC-11 (Margulies.DH et al., Cell (1976) 8, 405-415), SP2 /0 (Shulman, M. et al., Nature (1978) 276, 269-270), FO (deSt. Groth, SF et al., J. Immunol. Methods (1980) 35, 1-21), S194 ( Trowbridge, ISJ Exp. Med. (1978) 148, 313-323), and R210 (Galfre, G. et al., Nature (1979) 277, 131-133).
[063] Fusion between the immunized cell and the myeloma cell can be performed basically according to a known method, for example, such as the technique of Kohler and Milstein (Kohler, G. and Milstein, C., Methods Enzymol. (1981) 73, 3-46).
[064] More specifically, the above cell fusion is performed, for example, in the presence of a cell fusion accelerator in a conventional nutrient medium. As fusion accelerator, polyethylene glycol (PEG), Sendai virus (HVJ), or similar is used. If desired, an auxiliary agent, such as dimethylsulfoxide, can be added and used in order to increase the melting efficiency.
[065] The relationship of immunized cells and myeloma cells to be used in the present invention can be arbitrarily established. For example, the number of immunized cells that are preferably used is one to ten times the number of myeloma cells. As the culture medium to be used for the cell fusion mentioned above, a RPMI1640 culture medium suitable for the proliferation of the above mentioned myeloma cell line, a MEM culture medium, and other culture media commonly used for this can be used. type of cell culture. In addition, fluid that is supplemental to the serum, such as fetal bovine serum (FBS), can be used in conjunction with it.
[066] Cell fusion can be performed by mixing predetermined amounts of the above immunized cells and myeloma cells in the aforementioned culture medium, and a PEG solution (for example, it has an average molecular weight ranging from about 1000 to 6000), pre-warmed to about 37°C is added normally at a concentration of 30% to 60% (w/v) and mixed, thus forming a culture containing hybridomas of interest. Then, an appropriate culture medium is successively added to the culture thus obtained, which is then centrifuged to remove the supernatant, and this process is repeated to remove cell fusion agent or the like, which is not preferable for hybridoma growth.
[067] The hybridomas thus obtained are cultured by selection in a customary selection culture medium (eg, a HAT culture medium containing hypoxanthine, aminopterin and thymidine). Culture in this HAT culture medium continues for a sufficient period of time (generally several days to several weeks) so that cells (unfused cells) that are not of the desired hybridoma die. Subsequently, screening and simple cloning of the hybridoma producing an antibody of interest is performed using the general limiting dilution method.
[068] The above hybridomas are obtained by immunizing a non-human animal with an antigen. In addition to this method, hybridomas that produce a human antibody that has desired activity (eg, cell proliferation suppression activity) can also be obtained in vitro by sensitizing human lymphocytes, such as human lymphocytes that have been infected with the EB virus. , with a protein, a protein expressing cell, or a lysate thereof, followed by fusion of the sensitized lymphocytes with myeloma cells of human origin that have a permanently dividing capacity, such as U266 (Accession No: TIB196 ).
[069] The hybridoma thus prepared that produces a monoclonal antibody of interest can be subcultured in general culture medium and can be stored in liquid nitrogen for a long period of time.
[070] Specifically, a hybridoma can be prepared by immunization by a general immunization method using, as a sensitizing antigen, a desired antigen or a cell expressing the desired antigen, fusing the immunized cell thus obtained with a parent cell known by a general method of cell fusion, and then a monoclonal antibody producing cell (eg, a hybridoma) is screened by a general screening method.
[071] As a mouse producing human antibodies, a KM mouse (Kirin Pharma/Medarex) and a Xeno mouse (Amgen) are known (for example, International Patent Application Publications WO 02/43478 and WO 02/092812), by example. When such a mouse is immunized with the CAPRIN-1 protein or a fragment of it, a complete human polyclonal antibody can be obtained from the blood. In addition, splenocytes are collected from the immunized mouse and then a human-like monoclonal antibody can be prepared using a method for fusion with myeloma cells.
[072] An antigen can be prepared according to a method using animal cells (JP Patent Publication (Kohyo) No. 2007-530068) or baculovirus (eg International Publication WO98/46777), for example. When an antigen has low immunogenicity, the antigen can be linked to a macromolecule that has immunogenicity, such as albumin, and then immunization is performed.
[073] Additionally, an antibody gene is cloned from said hybridoma and then incorporated into an appropriate vector. The vector is then introduced into a host, and then the genetically recombined antibody produced using genetic recombination techniques can be used (eg, see Carl, AK Borrebaeck, James, W. Larrick, THERAPEUTIC MONOCLONAL ANTIBODIES, published in the UK by MACMILLAN PUBLISHERS LTD, 1990). Specifically, cDNA for a variable region (V region) of an antibody is synthesized from hybridoma mRNA using a reverse transcriptase. When DNA encoding the V region of an antibody of interest can be obtained, the DNA is ligated to DNA encoding the constant region (C region) of the desired antibody, and then the resulting fusion product is incorporated into a vector of expression. Alternatively, DNA encoding the V region of an antibody can be incorporated into an expression vector containing the DNA for the C region of an antibody. At this point, the DNA can be incorporated into an expression vector so that it is expressed under the control of expression control regions, such as an enhancer and promoter. The host cells are then transformed with the expression vector so that the antibody can be expressed.
[074] The anti-CAPRIN-1 antibody of the present invention is characterized by being a monoclonal antibody. Examples of a human monoclonal antibody include monoclonal antibodies, monoclonal antibodies from non-human animals (for example, a mouse monoclonal antibody, a rat monoclonal antibody, a rabbit monoclonal antibody, and a chicken monoclonal antibody), and chimeric monoclonal antibodies. A monoclonal antibody can be prepared by cultivating a hybridoma obtained by fusing spleen cells (spleenocytes) from a non-human mammal (eg, a mouse, a human antibody-producing mouse, a chicken or rabbit) immunized with a CAPRIN-1 protein, with a myeloma cell. A chimeric antibody is prepared by combining sequences from different animals, such as an antibody heavy chain comprising the heavy chain and light chain variable regions of a mouse antibody and the heavy chain and light chain constant regions of an antibody human. A chimeric antibody can be prepared using a known method. For example, a chimeric antibody can be obtained by ligating DNA encoding an antibody V region to DNA encoding a human antibody C region, incorporating the resulting fusion product into an expression vector, and then introducing the vector in a host for the production of the chimeric antibody. In the Examples described below, chimeric human-chicken monoclonal antibodies were prepared and therefore their antitumor effects were confirmed. These monoclonal antibodies comprise a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 42 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 46, wherein the VH region comprises the CDR1 represented by the amino acid sequence of SEQ ID NO:39, the CDR2 represented by the amino acid sequence of SEQ ID NO:40, and the CDR3 represented by the amino acid sequence of SEQ ID NO:41, and the region VL comprises CDR1 represented by the amino acid sequence of SEQ ID NO: 43, CDR2 represented by the amino acid sequence of SEQ ID NO: 44, and CDR3 represented by the amino acid sequence of SEQ ID NO: 45.
[075] A humanized antibody is a modified antibody that is also referred to as reshaped human antibody. A humanized antibody can be constructed by transplanting CDRs from an antibody from an immunized animal into the complementarity determining regions of a human antibody. General gene recombination techniques are also known.
[076] Specifically, DNA sequences designed to have each of the CDRs of a mouse or chicken antibody linked to each of the framework regions (FRs) of a human antibody are synthesized by the PCR method from various oligonucleotides, which are prepared so as to have overlapping portions on their terminal portions, for example. A humanized antibody can be obtained by linking the DNA thus obtained to a DNA encoding the constant region of a human antibody, incorporating the resulting fusion product into an expression vector, introducing the vector into a host, and thereby causing the host produces the gene product (see European Patent Publication No. 239,400 and International Publication WO 96/02576). Like FRs of a human antibody, which are bound through CDRs, FRs that allow the formation of an antigen-binding site with good complementarity determining regions are selected. If necessary, for the formation of an antigen-binding site that has the appropriate complementarity determining regions of a remodeled human antibody, the amino acids from the framework regions of an antibody variable region can be substituted (Sato, K. et al. ., Cancer Research 1993, 53: 851-856). Furthermore, the amino acids of FRs can be substituted for those from the framework regions of different human antibodies (see International Patent Publication WO 99/51743).
[077] As regions of the framework (frameworks - FRs) of a human antibody, which are linked through CDRs, the FRs that allow the formation of an antigen-binding site with good regions determining complementarity are selected. If necessary, for the formation of an antigen-binding site that has the appropriate complementarity determining regions of a remodeled human antibody, the amino acids from the framework regions of an antibody variable region can be substituted (Sato, K. et al. ., Cancer Research 1993, 53: 851-856).
[078] After the preparation of a chimeric antibody or a humanized antibody, the amino acids in the variable regions (for example, FR) or in the constant region can be replaced by other amino acids.
[079] Amino acid substitution is the substitution of, for example, less than 15, less than 10, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less or 2 or fewer amino acids and is preferably a substitution of 1 to 5 amino acids, and more preferably 1 or 2 amino acids. A substituted antibody must be functionally equivalent to an unsubstituted antibody. The substitution is, desirably, a conservative substitution of amino acid(s) between amino acids that have analogous properties, such as electric charge, side chain, polarity, aromaticity. Amino acids that have analogous properties can be classified, for example, into basic amino acids (lysine, arginine and histidine), acidic amino acids (aspartic acid and glutamic acid), uncharged polar amino acids (glycine, asparagine, glutamine, serine, threonine, cysteine and tyrosine), nonpolar amino acids (leucine, isoleucine, alanine, valine, proline, phenylalanine, tryptophan and methionine), branched chain amino acids (threonine, valine and isoleucine) and aromatic amino acids (phenylalanine, tyrosine, tryptophan and histidine).
[080] Examples of a modified antibody product include antibodies linked to various molecules such as polyethylene glycol (PEG). The substances to be bound in the modified antibody product of the present invention are not limited. Such a modified antibody product can be obtained by subjecting the antibody thus obtained to chemical modification. Methods for this have already been established in the state of the art.
[081] As used herein, the "functional equivalent" refers to an antibody that has a biological or biochemical activity similar to the antibody of the present invention, and specifically refers to a subject antibody that has the function of harming the tumor essentially without causing rejection after its application to a human, for example. An example of such activity includes the activity of suppressing cell proliferation or binding activity.
[082] As a method well known to those skilled in the art of preparing a polypeptide functionally equivalent to a polypeptide, a method for introducing mutations into a polypeptide is known. For example, those skilled in the art can prepare an antibody functionally equivalent to the antibody of the present invention by appropriately introducing a mutation into the antibody using site-directed mutagenesis (Hashimoto-Gotoh, T. et al., (1995) Gene 152, 271-275; Zoller, MJ., and Smith, M. (1983) Methods Enzymol.100, 468-500; Kramer, W. et al., (1984) Nucleic Acids Res. 12, 9441-9456; Kramer, W. and Fritz, HJ., (1987) Methods Enzymol. 154, 350-367; Kunkel, TA., (1985) Proc. Natl. Acad. Sci. USA 82, 488-492; Kunkel (1988) Methods Enzymol. , 2763-2766).
[083] An antibody that recognizes an epitope of a CAPRIN-1 protein recognized by the above anti-CAPRIN-1 antibody can be obtained by a method known to those skilled in the art. For example, such an antibody can be obtained by a method involving the determination of an epitope of a CAPRIN-1 protein recognized by an anti-CAPRIN-1 antibody, by a general method (eg epitope mapping) and in The preparation of an antibody is followed using a polypeptide which has an amino acid sequence contained in the epitope as an immunogen, or a method which involves the determination of an epitope of such an antibody prepared by a general method, and then selection is made. of an antibody that has the identical epitope to an anti-CAPRIN-1 antibody. As used herein, the term "epitope" refers to, in a mammal and preferably a human, a polypeptide fragment having antigenicity or immunogenicity. The minimum size unit thereof consists of about 7 to 12 amino acids, and preferably 8 to 11 amino acids.
[084] The affinity constant Ka (Kon/Koff) of the antibody of the present invention is preferably at least 107 M-1, at least 108 M1, at least 5x108 M-1, at least 109 M-1, at least 5x109 M-1, at least 1010 M-1, at least 5x1010 M-1, at least 1011 M-1, at least 5x1011 M-1, at least 1012 M-1 or at least 1013 M-1.
[085] The antibody of the present invention can be conjugated to an anti-tumor agent. Conjugation of the antibody with an antitumor agent can be accomplished by means of a spacer having a group reactive with an amine group, a carboxyl group, a hydroxyl group, a thiol group, or the like (e.g., a succinimidyl succinate group, a formyl group, a 2-pyridylthio group, a maleimidyl group, an alkoxy carbonyl group and a hydroxyl group).
[086] Examples of antitumor agents include the following antitumor agents known in the literature and the like, such as paclitaxel, doxorubicin, daunorubicin, cyclophosphamide, methotrexate, 5-fluorouracil, thiotepa, busulfan, improsulfan, piposulfan, benzodopa, carboquone, meturepa, uredo altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, trimethylolomelamine, bulatacin, bulatacinone, camptothecin, bryostatin, calistatin, cryptophycin 1, cryptophycin 8, dolastatin, duocarmycin, eleuterobin, pancratista, clintine, sarcodictine oxide mechlorethamine hydrochloride, melphalan, novembicin, phenesterin, prednimustine, trophosphamide, uracil mustards, carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine, caliceamycin, dinemycin, clodronate, esperamycin, camblemycin, aclablemycin tinomycin, carabicin, carminomycin, carzinophylline, chromomycin, dactinomycin, detorbicin, 6-diazo-5-oxo-L-norleucine, adriamycin, epirubicin, esorubicin, idarubicin, marcelomycin, mitomycin C, mycophenolic acid, nogalamycin, olivomycins, pefilomycins puromycin, chelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, denopterin, pteropterin, trimetrexate, fludarabine, 6-mercaptopurine, thiamiprine, thioguanine, ancitauridine, didoxyuridine, 6-azacitidine enocitabine, floxuridine, androgens (eg, calusterone, dromostanolone propionate, epitiostanol, mepitiostane and testolactone), aminoglutethimide, mitotane, trilostan, frolinic acid, aceglatone, aldophosphamide glycoside, aminolevulinic acid, enyluracil, bistraanthraxyl, ambusacyl defofamine, demecolcine, diaziquone, elfornithine, elliptin acetate, epothilone, etoglucide o, lentinan, lonidamine, maytansine, ansamitocin, mitoguazone, mitoxantrone, mopidanmol, nitraerin, pentostatin, fenamet, pyrarubicin, losoxantrone, podophylinic acid, 2-ethylhydrazide, procarbazine, razoxane, spirozizonic acid, trizizolan, trisquoxane, roridine A, anguidine, urethane, vindesine, dacarbazine, manomustine, mitobronitol, mitolactol, pipobroman, gacitosine, docetaxel, chlorambucil, gemcitabine, 6-thioguanine, mercaptopurine, cisplatin, oxaliplatin, carboplatin, vinblastine, iphosphatine , novantrone, teniposide, edatrexate, daunomycin, aminopterin, xeloda, ibandronate, irinotecan, topoisomerase inhibitor, difluoromethylornithine (DMFO), retinoic acid and capecitabine, and pharmaceutically acceptable salts and derivatives thereof.
[087] By administering the antibody of the present invention in combination with an antitumor agent, even greater therapeutic effects can be obtained. This technique is applicable before and after surgery on a cancer patient with CAPRIN-1 expression. Especially after surgery, more effective prevention of cancer recurrences or a prolonged survival period can be obtained against cancer expressing CAPRIN-1, which has been conventionally treated with an antitumor agent alone.
[088] Examples of antitumor agents to be administered in combination with the antibody of the present invention include the following antitumor agents known in the prior literature or the like, such as paclitaxel, doxorubicin, daunorubicin, cyclophosphamide, methotrexate, 5-fluorouracil, thiotepa, busulfan, improsulfan , piposulfan, benzodopa, carboquone, meturedopa, uredopa, altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, trimethylolomelamine, bulatacin, bulatacinone, camptothecin, bryostatin, calistatin, cryptophycin 1, cryptophycin, cryptomycin 8, cryptophycin, cryptophycin, cryptomycin 8, cryptophycin, cryptomycin 8 , chlornaphazine, colophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine hydrochloride oxide, melphalan, novembicin, phenesterin, prednimustine, trophosphamide, uracil mustards, carmustine, chlorozotocin, fotemustine, lodine,natomicin, nimustine icin, aclacinomycin, actinomycin, autramycin, azaserine, bleomycin, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycin, dactinomycin, detorbicin, 6-diazo-5-oxo-L-norleucine, adriamycin, epirubicin, esorubicin, cidalomicin , mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, chelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, denopterin, pteropterin, thimerguanbina, trimethexate, anamidine 6 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone, aminoglutethimide, mitotane, trilostan, frolinic acid, aceglatone, aldoracylphosphamide, aminophosphamide , bisantrene, edatraxate, defofamine, demecolcine, diaziquone, elforniti na, elliptin acetate, epothilone, ethoglucide, lentinan, lonidamine, maytansine, ansamitocin, mitoguazone, mitoxantrone, mopidanmol, nitraerin, pentostatin, fenamet, pyrarubicin, losoxantrone, podophilinic acid, 2-ethylcarbazozine, prophylazide , spirogermanium, tenuazonic acid, triaziquone, roridine A, anguidine, urethane, vindesine, dacarbazine, manomustine, mitobronitol, mitolactol, pipobromane, gacitosine, docetaxel, chlorambucil, gemcitabine, 6-thioguanine, mercaptopurine, cyliplatine , ifosfamide, mitoxantrone, vincristine, vinorelbine, novantrone, teniposide, edatrexate, daunomycin, aminopterin, xeloda, ibandronate, irinotecan, topoisomerase inhibitor, difluoromethylornithine (DMFO), retinoic acid and capecitabine, and pharmaceutically acceptable salts or derivatives (known) ) of the same. Of the examples mentioned above, particularly cyclophosphamide, paclitaxel, docetaxel and vinorelbine are preferably used.
[089] Alternatively, a radioactive isotope known in prior literature or similar, such as At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, Lu175 or Lu176, can be bound to the antibody of the present invention. A desired radioisotope is effective for tumor treatment or diagnosis.
[090] The antibody of the present invention is an antibody that has immunological reactivity with CAPRIN-1, or an antibody that specifically binds to CAPRIN-1, which exhibits a cytotoxic activity against cancer or suppression effect on tumor growth. The antibody must have a structure such that rejection is almost or completely avoided in a subject animal to which the antibody is administered. Examples of such an antibody include, when the subject animal is a human, a human antibody, a humanized antibody, a chimeric antibody (e.g., human-mouse chimeric antibody), a single chain antibody, and a bispecific antibody. These antibodies are: recombinant antibodies in which the heavy chain and light chain variable regions are from a human antibody; recombinant antibodies in which the heavy chain and light chain variable regions comprise the complementarity determining regions (CDRs) (CDR1, CDR2 and CDR3) from a non-human animal antibody; and the framework regions of a human antibody; or recombinant antibodies in which the heavy chain and light chain variable regions are from a non-human animal antibody; and the heavy chain and light chain constant regions are from a human antibody. Preferred antibodies are the first two antibodies mentioned.
[091] These recombinant antibodies can be prepared as follows by cloning DNA encoding a human anti-CAPRIN-1 monoclonal antibody (eg, a human monoclonal antibody, a mouse monoclonal antibody, a mouse monoclonal antibody, an antibody rabbit monoclonal, or chicken monoclonal antibody) from an antibody-producing cell, such as a hybridoma, by preparing the DNA encoding a light chain variable region and a heavy chain variable region of the antibody by an RT- PCR using the same as a template, and then determining the sequence of each light chain and heavy chain variable region or each sequence of CDR1, CDR2 and CDR3 based on the EU numbering system of Kabat (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institute of Health, Bethesda, Md. (1991)).
[092] In addition, DNA encoding each of the variable regions or DNA encoding each CDR is prepared using gene recombination techniques (Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1989)) or a DNA synthesizer. In the present invention, the human monoclonal antibody-producing hybridoma can be prepared by immunizing a human antibody-producing animal (eg, a mouse) with human CAPRIN-1, followed by fusion of spleen cells taken from the previously immunized animal with myeloma cells. Alternatively, DNAs encoding a light chain variable region and a human antibody heavy chain constant region are prepared as needed, using gene recombination techniques or using a DNA synthesizer.
[093] In the case of humanized antibody, DNA is prepared by replacing a CDR coding sequence in DNA encoding a light chain or heavy chain variable region derived from a human antibody, with a CDR coding sequence corresponding to that of a antibody derived from a non-human animal (for example, a mouse, rat, or chicken) and then linking the DNA thus obtained to DNA encoding a constant region of light chain or heavy chain derived from a human antibody . Thus, DNA encoding the humanized antibody can be prepared.
[094] In the case of the chimeric antibody, the DNA encoding a chimeric antibody can be prepared by ligating the DNA encoding a light chain or heavy chain variable region of an antibody from a non-human animal (eg, a mouse, a rat, or chicken) to the DNA encoding a human antibody light chain or heavy chain constant region.
[095] In the case of single-chain antibody, this antibody is an antibody prepared by linearly linking the heavy chain variable region to a light chain variable region by means of a linker. Thus, DNA encoding a single-chain antibody can be prepared by ligating together the DNA encoding a heavy chain variable region, and a DNA encoding a linker, and a DNA encoding a light chain variable region. In the present invention, a heavy chain variable region and a light chain variable region are either from a human antibody, or only the CDRs are replaced by CDRs from an antibody derived from a non-human animal (e.g., a mouse, a rat, and a chicken), although the other regions originate from a human antibody. Furthermore, the linker has 12 to 19 amino acids, and examples of it include (G4S)3 which has 15 amino acids (Kim, GB. et al., Protein Engineering Design and Selection 2007, 20 (9): 425 -432).
[096] In the case of bispecific antibody (diabody), this antibody is able to specifically bind to two different epitopes. For example, DNA encoding a bispecific antibody can be prepared by ligating DNA encoding an "A" heavy chain variable region to a DNA encoding a "B" light chain variable region to a DNA encoding a variable region of "B" heavy chain, and a DNA encoding a light chain variable region "A", in that order (in this case, the DNA encoding a light chain variable region "B" is linked to the DNA encoding a variable region heavy chain "B" through the DNA encoding the linker above). In this case, a heavy chain variable region and a light chain variable region are both from a human antibody, or only the CDRs are replaced by CDRs from an antibody derived from a non-human animal (eg, mouse, rat , or a chicken), although the other regions originate from a human antibody.
[097] The recombinant DNA prepared above is incorporated into one or a variety of vectors, these vectors are introduced into host cells (eg, mammalian cells, yeast or insect cells), then caused to (co)expression , so that the recombinant antibody can be prepared (PJ Delves, ANTIBODY PRODUCTION ESSENTIAL TECHNIQUES, 1997 WILEY; P. Shepherd and C. Dean., Monoclonal Antibodies, 2000 OXFORD UNIVERSITY PRESS; JW Goding., Monoclonal Antibodies: principles and practice, 1993 ACADEMIC PRESS).
[098] Examples of the antibody of the present invention prepared by the above method includes an antibody comprising a heavy chain variable region comprising SEQ ID NOS: 39, 40, and 41 and a light chain variable region comprising SEQ ID NOS: 43 , 44, and 45 (for example, antibody comprises the heavy chain variable region of SEQ ID NO: 42 and the light chain variable region of SEQ ID NO: 46).
[099] The amino acid sequences represented by SEQ ID NOS: 39, 40, and 41 are CDR1, CDR2 and CDR3 of a chicken antibody heavy chain variable region. Also, the amino acid sequences represented by SEQ ID NOS: 43, 44, and 45 are CDR1, CDR2 and CDR3 of a chicken antibody light chain variable region, respectively.
[100] Furthermore, the humanized antibody, chimeric antibody, single-chain antibody or bispecific antibody of the present invention is the following antibody, for example: (i) an antibody in which the heavy chain variable region comprises the amino acid sequence of SEQ ID NOS: 39, 40, and 41 and the amino acid sequences of the framework regions of a human antibody, and a light chain variable region comprises the amino acid sequences of SEQ ID NOS: 43, 44, and 45 and the amino acid sequences of the framework regions of a human antibody (for example, the antibody wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 42, and the chain variable region light comprises the amino acid sequence of SEQ ID NO: 46; and (ii) an antibody wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NOS: 39, 40, and 41, and the amino acid sequences of framework regions of a human antibody; and a heavy chain constant region comprises an amino acid sequence of a human antibody; and a light chain variable region comprising the amino acid sequences of SEQ ID NOS: 43, 44, and 45; and the amino acid sequences of the framework regions of a human antibody and a light chain constant region comprising an amino acid sequence of a human antibody (e.g., the antibody, wherein the heavy chain variable region comprises the sequence of amino acids of SEQ ID NO: 42, and the heavy chain constant region comprises the amino acid sequence of a human antibody, as well as a light chain variable region comprises the amino acid sequence of SEQ ID NO: 46, and a constant region chain comprising an amino acid sequence of a human antibody).
[101] In addition, human antibody heavy chain sequences and light chain constant regions and variable regions can be obtained from the NCBI (eg, in the US: GenBank, Unigene), for example. For example, the sequence with accession number J00228 can be referred to a human IgG1 heavy chain constant region, the sequence with accession number J00230 can be referred to as a human IgG2 heavy chain constant region, the sequence with the accession number X03604 may be referred to as a human IgG3 heavy chain constant region, the sequence with the accession number K01316 may be referred to as a human IgG4 heavy chain constant region, the sequences with the accession numbers V00557, X64135, X64133, and the like may be referred to as human K light chain constant regions, and sequences with accession numbers X64132, X64134, and the like may be referred to as human A light chain constant regions.
[102] The antibodies referred to above preferably have a cytotoxic activity and thus may exhibit antitumor effects.
[103] Furthermore, the specific sequences of heavy and light chain variable regions or CDRs in the above antibodies are given for illustrative purposes only, and therefore are not clearly limited to these specific sequences. A hybridoma capable of producing another human antibody or non-human animal antibody (eg, a mouse antibody) against human CAPRIN-1 is prepared, a monoclonal antibody that is produced by the hybridoma is collected, and then determined. whether the antibody is or is not the desired antibody having as indicators the property of immunological binding with human CAPRIN-1 and cytotoxic activity. After identifying a hybridoma that produces the target monoclonal antibody in this way, the DNA encoding the heavy chain and light chain variable region of the target antibody is prepared from the hybridoma as described above, and sequencing is performed, and then , the DNA is used for the preparation of another antibody.
[104] Furthermore, in the antibody of the present invention above, the sequence of each of the above-mentioned antibodies, and particularly the framework region sequence and/or the constant region sequence may have a substitution, a deletion or an addition of one or more (preferably 1 or 2) amino acids, as long as it retains the specific recognition specificity of CAPRIN-1. In this case, the term "miscellaneous" means 2 to 5, and preferably 2 or 3.
[105] The present invention further provides a DNA encoding the above antibody of the present invention, or a DNA encoding the above antibody heavy chain or light chain, or a DNA encoding the above antibody heavy chain or light chain variable region . Examples of such DNAs include, DNA encoding a heavy chain variable region comprising the nucleotide sequences encoding the amino acid sequences of SEQ ID NOS: 39, 40, and 41, and DNA encoding a light chain variable region comprising the nucleotide sequences encoding the amino acid sequences of SEQ ID NOS: 43, 44, and 45.
[106] The complementarity determining regions (CDRs) encoded by the DNA sequences are regions for determining antibody specificity. Therefore, the coding sequences of regions in an antibody other than the CDRs (more specifically, a constant region and a framework region) can be from other antibodies. In the present invention, examples of such "other antibodies" include antibodies derived from non-human organisms, and are preferably derived from humans in order to reduce side effects. Thus, in the case of the above DNA, the coding regions of each framework region and each heavy and light chain contact region preferably comprise the nucleotide sequences encoding corresponding amino acid sequences of a human antibody.
[107] Other examples of alternative DNA encoding the antibody of the present invention include DNA encoding a heavy chain variable region comprising the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 42 and a DNA in which the encoding region of a light chain variable region comprises the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 46. In that case, an example of the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 42 is the nucleotide sequence of SEQ ID NO: 49. Furthermore, an example of the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 46 is the nucleotide sequence of SEQ ID NO: 50. In these DNAs, the coding regions of each chain constant region heavy and light preferably comprise the nucleotide sequences that encode the corresponding amino acid sequences of a human antibody.
[108] The DNA of the present invention can be obtained by the above methods or by the following method. First, total RNA is prepared from an antibody-related hybridoma of the present invention using a commercial RNA extraction kit, then cDNA is synthesized with a reverse transcriptase using random primers or the like. Subsequently, the cDNA encoding an antibody is amplified by a PCR method using oligonucleotides of conserved sequences in each variable region of known mouse antibody heavy and light chain genes as primers. The coding sequence of a constant region can be obtained by amplifying a known sequence by the PCR method. The DNA nucleotide sequence can be determined by a conventional method such as inserting it into a plasmid or phage for sequencing.
[109] An anti-CAPRIN-1 antibody to be used in the present invention is considered to be an antibody that exhibits anti-tumor effects against cancer cells expressing CAPRIN-1 through the following mechanism:
[110] Antibody-dependent cytotoxicity (ADCC) activity of effector cells against cells expressing CAPRIN-1, and complement-dependent cytotoxicity (CDC) against cells expressing CAPRIN-1.
[111] Therefore, the activity of an anti-CAPRIN-1 antibody to be used in the present invention can be assessed, as specifically described in the Examples below, by measuring the ex vivo activity of ADCC or CDC against expressing cancer cells CAPRIN-1.
[112] An anti-CAPRIN-1 antibody to be used in the present invention, binds to a CAPRIN-1 protein in a cancer cell and exhibits antitumor effects due to the activity cited above, and thus is useful to treat or prevent a cancer. Specifically, the present invention provides a pharmaceutical composition for treating and/or preventing a cancer, which comprises an anti-CAPRIN-1 antibody as an active ingredient. When the anti-CAPRIN-1 antibody is used for administration to a human body (antibody therapy), it is preferably a human antibody or humanized antibody in order to decrease immunogenicity.
[113] In addition, the greater the binding affinity between an anti-CAPRIN-1 antibody and a CAPRIN-1 protein on the surfaces of cancer cells, the stronger antitumor activity of the anti-CAPRIN-1 antibody can be obtained. Therefore, when an anti-CAPRIN-1 antibody with high binding affinity for CAPRIN-1 protein can be acquired, strong anti-tumor effects can be expected, so application of the antibody as a pharmaceutical composition for treatment and/or preventing cancer becomes possible. The high affinity binding is desirably as follows. As described above, the binding constant (affinity constants) Ka (kon/koff) is preferably at least 107 M-1, at least 108 M-1, at least 5 *108 M-1, at least 109 M -1, at least 5 *109 M-1, at least 1010 M-1, at least 5 *1010 M-1, at least 1011 M-1, at least 5 *1011 M-1, at least 1012 M-1 or at least 1013 M-1. LINK TO CELLS EXPRESSING ANTIGEN
[114] The ability of an antibody to bind CAPRIN-1 can be specified by binding assay using the ELISA method, a Western blot method, immunofluorescence and flow cytometric analysis, or similar techniques such as those described in the Examples. STAINING BY IMMUNOHISTOCHEMISTRY
[115] An antibody that recognizes CAPRIN-1 can be tested for reactivity to CAPRIN-1 by an immunohistochemical method known to those skilled in the art, using frozen tissue sections fixed in acetone or fixed tissue sections embedded in paraffin , which is prepared from tissue samples obtained from a patient during surgery, or tissue samples obtained from an animal that has a heterotransplant inoculated with a cell line that expresses CAPRIN-1, either naturally or after transfection.
[116] An antibody reactive with CAPRIN-1 can be stained by a variety of immunohistochemical staining methods. For example, a goat anti-mouse antibody or goat anti-chicken antibody conjugated to horseradish peroxidase can perform the reaction, and a target antibody can be visualized. PHARMACEUTICAL COMPOSITION
[117] A target of the pharmaceutical composition to treat and/or prevent a cancer of the present invention is not particularly limited, as long as it is a cancer (cell) that expresses a CAPRIN-1 gene.
[118] The terms "tumor" and "cancer" used in the present invention refer to malignant neoplasms and are used interchangeably.
[119] The cancer to be subjected in the present invention is cancer that expresses genes encoding CAPRIN-1 proteins that have the amino acid sequences NE even numbered from SEQ ID NOS: 2 to 30. Examples of such cancer preferably include breast cancer, brain tumor, leukemia, lymphoma, lung cancer, mast cell tumor, kidney cancer, cervical cancer, bladder cancer, esophageal cancer, gastric cancer, or colorectal cancer.
[120] Examples of such specific cancer include, but are not limited to, breast adenocarcinoma, compound type breast adenocarcinoma, malignant mixed mammary gland tumor, intraductal papillary adenocarcinoma, lung adenocarcinoma, squamous cell carcinoma, small cell carcinoma , large cell carcinoma, glioma which is a tumor of neural epithelial tissue, ependymoma, neurocytoma, fetal neuroectodermal tumor, schwannoma, neurofibroma, meningioma, chronic lymphocytic leukemia, lymphoma, gastrointestinal lymphoma, digestive lymphoma, small cell and medium cell lymphoma, cancer of cecum, ascending colon, descending colon, transverse colon cancer, sigmoid colon and rectal cancer.
[121] Furthermore, preferred individuals are mammals, including primates, pets, domestic animals, breed animals, and the like, and are particularly preferably humans, dogs, and cats.
[122] When the antibody used in the present invention is used as a pharmaceutical composition, it can be formulated by a method known to those skilled in the art. For example, the antibody can be used parenterally in the form of an injectable preparation, such as an aseptic solution or suspension made with water or with a pharmaceutically acceptable solution other than water. For example, it can be formulated by mixing a unit dosage form required by generally accepted pharmaceutical practice, in suitable combination with a carrier or pharmacologically acceptable medium, specifically, sterile water or saline, vegetable oil, an emulsifier, a suspension, a surface active agent, a stabilizer, a flavoring compound, an excipient, a vehicle, an antiseptic, a binding agent, and the like. The amounts of active ingredients in these preparations are determined so that an adequate dose within the indicated range can be obtained.
[123] A composition for aseptic injection may be prescribed in accordance with general pharmaceutical practice using a vehicle such as distilled water for injection.
[124] Examples of an aqueous solution for injection include saline solution, isotonic solution containing dextrose or other adjuvants such as D-sorbitol, D-mannose, D-mannitol, and sodium chloride. These examples can be used in combination with a suitable solubilizing agent such as alcohol, especially ethanol and polyalcohol (eg propylene glycol and polyethylene glycol), and a nonionic surfactant (surfactant) (eg polysorbate 80® and HCO-60).
[125] Examples of oils include sesame oil and soybean oil, which can be used in combination with a solubilizing agent such as benzyl benzoate or benzyl alcohol. In addition, buffering agents such as phosphate buffer or sodium acetate buffer, calming agents such as procaine hydrochloride, a stabilizer such as benzyl alcohol, phenol, or antioxidants can be mixed with it. A suitable ampoule is usually filled with the injection solution thus prepared.
[126] Administration is oral or parenteral administration and is preferably parenteral administration. Specific examples of the route of administration include injection, transnasal administration, pulmonary administration and transdermal administration. Examples of injection include intravenous injection, intramuscular injection, intraperitoneal injection, and subcutaneous injection, so that systemic or local administration is possible.
[127] In addition, administration methods can be appropriately selected depending on the patient's age, body weight, sex, symptoms, and others. The dosage by administering a pharmaceutical composition containing an antibody or polynucleotide encoding the antibody may be selected from the range between 0.0001 mg and 1000 mg per kg of body weight, for example. Alternatively, the dosage can be selected, for example, from the range between 0.001 mg/body and 100,000 mg/body per patient. However, the dosage range is not always limited to these numerical values. The dosage and method of administration varies depending on the patient's body weight, age, sex, symptoms, and the like, but can be suitably selected by those skilled in the art.
[128] The above pharmaceutical composition containing the antibody or a fragment thereof of the present invention is administered to a subject such that cancer, preferably breast cancer, brain tumor, leukemia, lung cancer, lymphoma, mast cell tumor, kidney cancer , cervical cancer, bladder cancer, esophageal cancer, gastric cancer, colorectal cancer, can be treated and/or prevented.
[129] The present invention further encompasses a method of treating and/or preventing a cancer, comprising administering to a subject the pharmaceutical composition of the present invention in combination with the antitumor agent exemplified above or a pharmaceutical composition containing said antitumor agent. The antibody or fragment thereof of the present invention and the anti-tumor agent can be administered simultaneously or separately to a subject. They can be managed separately, regardless of the order of administration. Intervals of administration, dosage, route of administration, and frequency of administration may be appropriately selected by a specialist. Examples of another pharmaceutical formulation to be administered simultaneously include pharmaceutical compositions obtained by mixing the antibody or fragment thereof of the present invention with an antitumor agent in a pharmaceutically acceptable vehicle (or medium) followed by the formulation. In addition, the above pharmaceutical composition containing an antitumor agent and the formulation, explanations regarding the prescription, formulation, route of administration, dose, cancer to be treated and the like are applicable for the administration of a pharmaceutical composition containing the antibody of the present invention and the formulation.
[130] Therefore, the present invention also provides a pharmaceutical combination for treating and/or preventing a cancer, comprising the pharmaceutical composition of the present invention and the pharmaceutical composition exemplified above containing an antitumor agent.
[131] Furthermore, the present invention provides a pharmaceutical composition for treating and/or preventing a cancer, comprising the antibody or fragment thereof of the present invention and an antitumor agent together with a pharmacologically acceptable carrier. POLYPEPTIDE AND DNA
[132] The present invention also provides the following polypeptides or DNAs related to the above antibodies. (i) A polypeptide comprising the amino acid sequence of SEQ ID NO: 42, and the DNA encoding the polypeptide, wherein the DNA comprises the nucleotide sequences of SEQ ID NO: 49. (ii) A polypeptide comprising the amino acid sequence of SEQ ID NO: 46, and the DNA encoding the polypeptide, wherein the DNA comprises the nucleotide sequences of SEQ ID NO: 50. (iii) A heavy chain CDR polypeptide selected from the amino acid sequences represented by SEQ ID NOS: 39, 40 and 41, and the DNA encoding the polypeptide. (iv) A light chain CDR polypeptide selected from the amino acid sequences represented by SEQ ID NOS: 43, 44 and 45, and the DNA encoding the polypeptide.
[133] These polypeptides and DNAs can be prepared using the gene recombination techniques as described above. BRIEF DESCRIPTION OF THE INVENTION
[134] The present invention explained above is summarized as follows. (1) A pharmaceutical composition for treating and/or preventing a cancer, comprising an antibody comprising a heavy chain variable region comprising SEQ ID NOS: 39, 40 and 41; and a light chain variable region comprising SEQ ID NOS: 43, 44, and 45 or a fragment thereof as an active ingredient and which has immunological reactivity with a CAPRIN-1 protein. (2) The pharmaceutical composition according to item (1) in which the cancer is breast cancer, brain tumor, leukemia, lymphoma, lung cancer, mast cell tumor, kidney cancer, cervical cancer, esophageal cancer, gastric cancer , bladder cancer, or colorectal cancer. (3) The pharmaceutical composition according to item (1) or (2), characterized in that said antibody is a human antibody, humanized antibody, chimeric antibody, single-chain antibody or a bispecific antibody. (4) An antibody comprising a heavy chain variable region comprising SEQ ID NOS: 39, 40 and 41; and a light chain variable region comprising SEQ ID NOS: 43, 44, and 45, and which has immunological reactivity with a CAPRIN-1 protein. (5) The antibody according to item (4) above is characterized in that the antibody is a human antibody, humanized antibody, chimeric antibody, single-chain antibody or bispecific antibody. (6) A pharmaceutical combination for treating and/or preventing a cancer, comprising the pharmaceutical composition of any one of items (1) to (3) above and a pharmaceutical composition containing an antitumor agent. (7) A method of treating and/or preventing a cancer, comprising administering to a subject a pharmaceutical composition of any one of items (1) to (3) above; or the antibody of any one of items (3) to (5) above or a fragment thereof. (8) A method for treating and/or preventing a cancer, comprising using pharmaceutical compositions of the pharmaceutical combination of item (6) above, in combination, in a subject. EXAMPLES
(135) The present invention is more specifically described based on examples, but the scope of the present invention is not limited by these specific examples. EXAMPLE 1 IDENTIFICATION OF NEW CANCER ANTIGEN PROTEINS BY THE SEREX METHOD (1) cDNA LIBRARY PREPARATION
(136) Total RNA was extracted from the testis tissue of a healthy dog by a guanidine acid-phenol-chloroform method. PolyA RNA was purified according to the protocols provided with an "Oligotex-dT30 mRNA" purification kit (Takara Shuzo Co., Ltd.) using the kit.
(137) A dog testis cDNA phage library was synthesized using the mRNA thus obtained (5 µg). For the preparation of the cDNA phage library, a cDNA synthesis kit, a “ZAP-DNA synthesis kit”, and a cloning kit “ZAP-cDNA gigapack III gold clonning kit” (Stratagene) were used and the library was used. prepared according to protocols included in the kits. The size of the prepared cDNA phage library was 7.73 x 105 pfu/ml. (2) SELECTION OF THE CDNA LIBRARY USED THE SERUM
[138] Immunoselection was performed using the dog testis cDNA phage library prepared above. Specifically, an Escherichia coli (XL1-Blue MRF') host was infected with the phage such that 2210 clones were present on a 0 90 x 15 mm NZY agarose plate. Cells were cultured at 42°C for 3 to 4 hours to cause plaque formation. The plate was covered with a nitrocellulose membrane (Hybond C extra: GE Healthcare Bio-Science) impregnated with IPTG (isopropyl-β-D-thiogalactoside) at 37°C for 4 hours. Proteins were induced, expressed, and then transferred to the membrane. Subsequently, the membrane was recovered, immersed, and shaken in TBS (10 mM Tris-HCl, 150 mM NaCl pH 7.5) containing 0.5% skim milk powder at 4°C overnight. , so the non-specific reaction was suppressed. The filter was allowed to react with dog serum diluted 500 times at room temperature for 2 to 3 hours.
[139] Like the above serum from dogs with cancer, sera collected from dogs with breast cancer were used. Sera were stored at -80 °C and then subjected to pre-treatment immediately before use. Pretreatment for serum was carried out by the following method. Specifically, the host Escherichia coli (XL1-blure MRF') was infected with "X ZAP Express" expressed phage into which no foreign gene was introduced, and then plate-cultured with NZY medium at 37°C overnight. Subsequently, a 0.2 M NaHCO3 buffer (pH 8.3) containing 0.5 M NaCl was added to the plate and then the plate was left to stand at 4°C for 15 hours. Supernatants were collected as Escherichia coli/phage extracts. Then, the collected Escherichia coli/phage extracts were passed through an NHS-column (GE Healthcare Bio-Science) in order to immobilize the Escherichia coli/phage-derived protein. Serum from a dog with cancer was passed through the column to which the protein was immobilized by reaction, thus removing Escherichia coli and phage-adsorbed antibodies from the serum. Each whey fraction that passed through the column was diluted 500 times with TBS containing 0.5% skim milk powder, and the resultant was used as immunoselection material.
[140] A membrane, to which the treated serum and the fusion protein cited above were subjected to the blotting technique, was washed 4 times with TBS-T (0.05% Tween 20/TBS). The membrane was reacted with goat anti-dog IgG antibody (goat anti-dog IgG-h+i conjugated to HRP: BETHYL Laboratories), diluted 5,000 times, as a secondary antibody with TBS containing 0.5% milk in skimmed powder at room temperature for 1 hour. Detection was performed by enzymatic color reaction using an NBT/BCIP reaction solution (Roche). Colonies corresponding to the positive site of the color reaction were collected from 090 x 15 mm NZY agarose plates, and then dissolved in 500 μl of SM buffer (100 mM NaCl, 10 mM MgClSO4, 50 mM Tris-HCl , 0.01% gelatin, pH 7.5). Until unification of positive colonies for the color reaction, secondary selection and tertiary selection were repeated by a method similar to that described above. Thus, 30940 phage clones that reacted with serum IgG were sorted so that 5 positive clones were isolated. (3) HOMOLOGY SURVEY FOR THE ISOLATED ANTIGEN GENE
[141] A procedure for converting phage vectors to plasmid vectors was performed for the 5 positive clones isolated by the method described above for the purpose of submitting the clones to nucleotide sequence analysis. Specifically, 200 µL of an Escherichia coli host solution (XL1-Blue MRF') prepared to give an absorbance in OD600 of 1.0; 250 µL of a purified phage solution, and 1 µL of “ExAssist helper phage” helper phage (Stratagene) were mixed and allowed to react at 37°C for 15 minutes. Then 3 ml of LB medium was added, the cells were cultured at 37°C for 2.5 to 3 hours, and then the resultant was immediately placed in a 70°C water bath for a 20 minute incubation. . Centrifugation was performed at 4 °C, 1000 x g for 15 minutes and then the supernatant was collected as a phagemid solution. Subsequently, 200 µl of a solution prepared from the host phagemid Escherichia coli SOLR to give an absorbance at OD600 of 1.0; and 10 µL of the purified phage solution were mixed, followed by 15 minutes of reaction at 37 °C. 50 μl of the resulting solution was plated on LB agar medium containing ampicillin (at a final concentration of 50 μg/ml) and then grown overnight at 37 °C. A single transformed SOLR colony was collected and then cultured in LB medium containing ampicillin (at a final concentration of 50 μg/ml) at 37 °C. After cultivation, plasmid DNA containing an insert of interest was purified using a “QIAGEN plasmid Miniprep Kit” (QIAGEN).
[142] The purified plasmid was subjected to analysis of the entire sequence of the inserted segment by the “primer walking” method using the T3 primer of SEQ ID NO: 31 and the T7 primer of SEQ ID NO: 32. The gene sequences of SEQ ID NOS: 5, 7, 9, 11, and 13 were obtained by means of sequence analysis. Using the nucleotide sequences of the genes and their amino acid sequences (SEQ ID NOS: 6, 8, 10, 12, and 14), the BLAST homology search program (http://www.ncbi.nlm) .nih.gov/BLAST/) was conducted to search for homology with known genes. As a result, it was revealed that all five genes obtained were genes encoding CAPRIN-1. Sequence identities among the five genes were 100% with respect to nucleotide sequence and 99% with respect to amino acid sequence in the regions to be translated into proteins. The sequence identities of these genes with the homologous human coding genes were 94% with respect to the nucleotide sequence and 98% with respect to the amino acid sequence in the regions to be translated into proteins. The nucleotide sequences of the human homologs are represented by SEQ ID NOS: 1 and 3 and the amino acid sequences thereof are represented by SEQ ID NOS: 2 and 4. In addition, the sequence identities of the dog genes obtained with the genes coding from cattle homologs were 94% with respect to nucleotide sequence and 97% with respect to amino acid sequence in regions that are translated into proteins. The nucleotide sequence of the cattle homolog is represented by SEQ ID NO: 15 and the amino acid sequence thereof is represented by SEQ ID NO: 16. In addition, the sequence identities of the human homolog coding genes with the genes coding for cattle homolog were 94% with respect to nucleotide sequence and 93% to 97% with respect to amino acid sequence in regions that are translated into proteins. Furthermore, the sequence identities of the dog genes obtained with the coding genes of horse homologs were 93% with respect to nucleotide sequence and 97% with respect to amino acid sequence in the regions that are translated into proteins. The nucleotide sequence of the horse homolog is represented by SEQ ID NO: 17 and the amino acid sequence thereof is represented by SEQ ID NO: 18. In addition, the sequence identities of the human homolog coding genes with the genes coding for horse homolog were 93% with respect to nucleotide sequence and 96% with respect to amino acid sequence in regions that are translated into proteins. Furthermore, the sequence identities of the dog genes obtained with the coding genes of mouse homologs were from 87% to 89% with respect to the nucleotide sequence and from 95 to 97% with respect to the amino acid sequence in the regions that are translated. into proteins. The nucleotide sequences of the mouse homologs are represented by SEQ ID NOS: 19, 21, 23, 25 and 37; and the amino acid sequences thereof are represented by SEQ ID NOS: 20, 22, 24, 26 and 28. In addition, the sequence identities of the human homolog coding genes with the mouse homolog coding genes were 89% to 91% with respect to nucleotide sequence and were 95% to 96% with respect to amino acid sequence in regions that are translated into proteins. Furthermore, the sequence identities of the dog genes obtained with the coding genes of homologues of chicken were 82% with respect to the nucleotide sequence and 87% with respect to the amino acid sequence in the regions that are translated into proteins. The nucleotide sequence of the chicken homolog is represented by SEQ ID NO: 29 and the amino acid sequence thereof is represented by SEQ ID NO: 30. In addition, the sequence identities of the human homolog coding genes with the coding genes of the chicken homolog were 81% to 82% with respect to nucleotide sequence; and 86% with respect to the amino acid sequence in the regions that are translated into proteins. (4) ANALYSIS OF GENE EXPRESSION IN EACH TISSUE
[143] Gene expression obtained by the method described above was examined in normal tissues of dogs and humans and in different cell lines by the RT-PCR method. The reverse transcription reaction was carried out as follows. Specifically, total RNA was extracted from 50 mg to 100 mg of tissue or 5 to 10 x 106 cells of the cell line using a Trizol reagent (Invitrogen) according to the attached protocols. The cDNA was synthesized with the total RNA using a RT-PCR synthesis system "Superscript First-Strand Synthesis System" (Invitrogen) according to the manufacturer's protocol. PCR was performed as follows using primers of SEQ ID NOS: 33 and 34 specific for the genes obtained. Specifically, the reagents and a follow-up buffer were added to 0.25 μL of the sample, prepared by the reverse transcription reaction in a total volume of 25 μL, so that the resultant contained the above primers at 2 μM each, dNTPs 0, 2 mM of each, and 0.65U of ExTaq polymerase (Takara Shuzo Co., Ltd.). PCR was performed by repeating a cycle of 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 30 seconds for 30 cycles using a Thermal Cycler (BIO RAD). The above gene-specific primers are capable of amplifying the region from nucleotides 206 to 632 in the nucleotide sequence of SEQ ID NO: 5 (CAPRIN-1 dog gene) and the region from nucleotides 698 to 1124 in the sequence of nucleotides of SEQ ID NO: 1 (human CAPRIN-1 gene). As a control for comparison, GAPDH specific primers of SEQ ID NOS: 35 and 36 were also used simultaneously. As a result, as shown in Fig. 1, strong expression in the testis was observed among tissues from normal dogs, while expression was observed in tissues from breast cancer and dog adenocarcinoma. In addition, the observation of the expression of the human homolog from the obtained genes was also carried out. As a result, similarly to the case of the dog CAPRIN-1 gene, expression could be observed only in the testis among normal tissues. However, in the case of cancer cells, expression has been detected in many types of cancer cell lines, including breast cancer, brain tumor, leukemia, lung cancer, and esophageal cancer cell lines. Expression has been observed especially in many of the breast cancer cell lines. These results were confirmed by the results that with the exception of testis tissue the expression of CAPRIN-1 is not observed in normal tissues, whereas CAPRIN-1 was expressed in cancer cells and specifically in many breast cancer cell lines .
[144] In Fig. 1, reference number 1 on each vertical axis indicates the gene expression patterns identified above, and reference number 2 indicates the expression patterns of the GAPDH gene as a control. (5) IMMUNOHISTOCHEMICAL STAINING (5)-1 CAPRIN-1 EXPRESSION IN NORMAL MOUSE AND DOG TISSUES
[145] Mice (Balb/c, females) and dogs (beagles, females) were exsanguinated under ether anesthesia and ketamine/isoflurane anesthesia. After laparotomy, each organ (stomach, liver, eyeball, thymus, muscle, bone marrow, uterus, small intestine, esophagus, heart, kidney, salivary gland, large intestine, mammary gland, brain, lung, skin, supra-gland kidney, ovary, pancreas, spleen, and bladder) was transferred to a 10 cm plate containing PBS. Each organ was cut in PBS and then subjected to overnight fixation perfusion in 0.1 M phosphate buffer (pH 7.4) containing 4% paraformaldehyde (PFA). The perfusion solution was discarded, the tissue surface of the organs was washed with PBS, a PBS solution containing 10% sucrose was added to a 50 ml centrifuge tube, each tissue was added to the tube, and then , the tube was shaken using a rotor at 4°C for 2 hours. The solution was replaced with a PBS solution containing 20% sucrose, and then allowed to stand at 4°C until the tissue sank. The solution was replaced with a PBS solution containing 30% sucrose and then allowed to stand at 4°C until the tissue sank. The tissue was removed and then necessary portions were excised with a surgical scalpel. Then, an OCT (Tissue Tek) compound was added to the tissue so that it was completely applied to the tissue surface, and then the tissue was placed in a cryomold. The cryomold was placed on dry ice for quick freezing. Then the tissue was cut from 10 µm to 20 µm using a cryostat (Leica). The sections were air dried on glass slides using a hair dryer for 30 minutes to prepare the cut tissue mounted on a glass slide. Then, each sample was placed in a staining bottle filled with PBS-T (saline solution containing 0.05% Tween 20) and then subjected to PBS-T replacement three times every 5 minutes. Excess water around the cuts was removed with Kimwipes, and then the cuts were circled using a “DAKOPEN” (DAKO) pen. As blocking solutions, a MOM mouse Ig blocking reagent (Vectastain) and a PBS-T solution containing 10% FBS were placed on the slides over the mouse and dog tissue, respectively, and then left to rest in humid chamber at room temperature for 1 hour. Then a 10 μg/ml anti-CAPRIN-1 monoclonal antibody solution (monoclonal antibody #1 prepared in Example 4) adjusted with a blocking solution, which reacts with cancer cell surfaces and comprises the variable region of chain heavy of SEQ ID NO: 42 and the light chain variable region of SEQ ID NO: 46, was placed over the tissue on the slide and then left to rest overnight in a humid chamber at 4°C. 10-minute washes were performed with PBS-T 3 times, and then a biotin-labeled anti-MOM IgG antibody (Vectastain) diluted 250 times with the blocking solution was placed, and then the slides were incubated in room temperature for 1 hour in a humid chamber. After ten (10) minutes of washing with PBS-T 3 times, an avidin-biotin ABC reagent (Vectastain) was placed on the slides, and then the sample was left to rest in a humid chamber at room temperature for 5 minutes . After ten (10) minutes of washing with PBS-T 3 times, a DAB dye solution (10 mg DAB + 30% H2O2 10 μl/0.05 M Tris-HCl (pH 7.6)) was added 50 ml), and then the sample was left to rest in a humid chamber at room temperature for 30 minutes. After washing with distilled water, a hematoxylin reagent (DAKO) was placed on the sample and the sample was allowed to stand at room temperature for 1 minute and then washed with distilled water. The glass slide was immersed in 70%, 80%, 90%, 95%, and finally 100% ethanol solutions for 1 minute each, then the slides were left overnight in xylene. The glass slides were removed, sealed with mounting medium "Glycergel Mounting Medium" (DAKO), and then analyzed. As a result, CAPRIN-1 expression was observed slightly within cells of each tissue of salivary glands, kidney, colon and stomach, but expression of the same was not observed on cell surfaces. Furthermore, expression in tissues from other organs was not observed. (5)-2 CAPRIN-1 EXPRESSION IN DOG BREAST CANCER TISSUE
[146] Freeze-slice slides were prepared by a method similar to that described above using 108 breast cancer specimens frozen from tissue from dogs pathologically diagnosed as having malignant breast cancer, and immunohistochemical staining was performed using the monoclonal antibody #1, prepared in Example 4. As a result, CAPRIN-1 expression was observed in 100 of 108 samples (92.5%) and CAPRIN-1 was strongly expressed on the surface of cancer cells with a degree of atypism particularly high. (5)-3 CAPRIN-1 EXPRESSION IN HUMAN BREAST CANCER TISSUE
[147] Immunohistochemistry staining was performed using 188 human breast cancer tissue specimens in a tissue array of paraffin-embedded human breast cancer (BIOMAX) tissue array. After 3 hours of treating the breast cancer tissue array in matrix at a temperature of 60°C, the matrix was placed in a xylene staining bottle, followed by xylene replacement three times every 5 minutes. Then, a similar process was carried out with ethanol and PBS-T instead of xylene. The human breast cancer tissue matrix was placed in a staining bottle with 10 mM citrate buffer (pH 6.0) containing 0.05% Tween 20. After 5 minutes of treating at 125 °C, the matrix was left. standing at room temperature for 40 minutes or more. Excess water around the slices was removed with Kimwipes, and the slices were circled with a DAKOPEN pen, and an endogenous peroxidase blocker (DAKO) was added dropwise in appropriate amounts. Then tissue samples in matrix were allowed to rest at room temperature for 5 minutes, tissue samples in matrix were placed in a staining bottle with PBS-T, followed by PBS-T replacement three times every 5 minutes. As a blocking solution, a PBS-T solution containing 10% FBS was placed on the matrix, and then the matrix was allowed to stand in a humid chamber at room temperature for 1 hour. After incubation, a 10 µg/ml solution of monoclonal antibody #1 adjusted with a solution of PBS-T containing 5% FBS, an antibody that reacts with the surface of cancer cells and which was prepared in Example 4, was placed. and the tissue array arrangement was left to rest overnight in a humid chamber at 4 °C. After ten (10) minutes of washing with PBS-T for 3 times, a conjugated polymer labeled with peroxidase "Peroxidase Labeled Polymer Conjugated (DAKO)" was added dropwise on the slides in appropriate amounts, and then the tissue arrangement in matrix was left to rest in a humid chamber at room temperature for 30 minutes. After ten (10) minutes after washing with PBS-T 3 times, a DAB dye solution (DAKO) was placed on the slides and then incubated at room temperature for about 10 minutes. The dye solution was discarded, and 10 minute washes with PBS-T were performed 3 times, and then washes with distilled water. The tissue array array was immersed in solutions of 70%, 80%, 90%, 95%, and finally 100% ethanol, for 1 minute each, then rested overnight in xylene. The glass slides were removed, sealed with mounting medium "Glycergel Mounting Medium" (DAKO), and then analyzed. As a result, strong expression of CAPRIN-1 was observed in a total of 138 of the 188 breast cancer tissue specimens (73%). (5)-4 CAPRIN-1 EXPRESSION IN HUMAN MALIGNANT BRAIN TUMOR
[148] Immunohistochemistry staining was performed according to a method similar to that used in item (5)-3 above with 247 tissue specimens of malignant brain tumors in a tissue array of human malignant brain tumors embedded in paraffin (BIOMAX), using monoclonal antibody #1 prepared in Example 4. As a result, strong expression of CAPRIN-1 was observed in a total of 227 of the 247 human malignant brain tumor tissue specimens (92%). (5)-5 CAPRIN-1 EXPRESSION IN LYMPHONODE WITH HUMAN BREAST CANCER METASTASIS
[149] Immunohistochemistry staining was performed according to a method similar to that used in item (5)-3 above with 150 tissue specimens of lymph node with breast cancer metastasis in a tissue array (tissue array) of lymph nodes with metastasis from paraffin-embedded human breast cancer (BIOMAX) using monoclonal antibody #1 prepared in Example 4. As a result, strong expression of CAPRIN-1 was observed in 136 of a total of 150 metastatic lymph node tissue specimens of breast cancer (90%). Specifically, it was revealed that CAPRIN-1 was also strongly expressed in cancer tissues that had breast cancer metastases. (5)-6 CAPRIN-1 EXPRESSION IN SEVERAL HUMAN CANCER TISSUES
[150] Immunohistochemistry staining was performed according to a method similar to the above, with specimens in different tissue array arrays embedded in human cancer tissue paraffin (BIOMAX), using monoclonal antibody #1, prepared in Example 4. As a result, strong expression of CAPRIN-1 was observed in esophageal cancer, colon cancer, rectal cancer, lung cancer, kidney cancer, bladder cancer and cervical cancer. EXAMPLE 2 PREPARATION OF A NEW HUMAN CANCER ANTIGEN PROTEIN (1) PREPARATION OF RECOMBINANT PROTEIN
[151] Based on the gene of SEQ ID NO: 1 obtained in Example 1, a recombinant protein from the homologous human gene was prepared by the following method. A PCR was performed in a total volume of 50 μL, with 1 μL of cDNA, two primers (SEQ ID NOS: 37 and 38, comprising the sequences for cleavage by the restriction enzymes SacI and XhoI) of 0.4 μM each, 0 .2 mM dNTP, and 1.25U PrimeStar HS polymerase (Takara Shuzo Co., Ltd.), prepared by adding the reagents and an accompanying buffer. Expression was confirmed by an RT-PCR method for the cDNA used among the various tissue- or cell-derived cDNAs prepared in Example 1. PCR was performed by repeating thermocycling at 98°C for 10 seconds and 68°C for 2 .5 minutes for 30 cycles using a Thermal Cycler Thermal Cycler (BIO RAD). The above two primers are able to amplify a coding region of the entire amino acid sequence of SEQ ID NO: 2. After PCR, the amplified DNA was subjected to 1% agarose gel electrophoresis, then a DNA fragment from about 2.1 kbp was purified using a QIAquick Gel Extraction Kit (QIAGEN).
[152] The DNA fragment thus purified was ligated to a PCR-Blunt cloning vector (Invitrogen). After transforming Escherichia coli with it, the plasmid was collected. It was verified by sequencing the fragment that the gene thus amplified has the sequence of interest. The plasmid which has a sequence corresponding to the sequence of interest was treated with the restriction enzymes SacI and XhoI and then purified with a QIAquick gel extraction kit. The gene sequence of interest was introduced into an Escherichia coli expression vector pET30a (Novagen), and treated with restriction enzymes SacI and XhoI. Recombinant protein fused to the His-tag could be produced using the vector. The plasmid was transformed into Escherichia coli for expression, BL21(DE3) and then expression was induced with 1 mM IPTG, so that the protein of interest was expressed in Escherichia coli. (2) RECOMBINANT PROTEIN PURIFICATION
[153] The recombinant Escherichia coli obtained above expressing the gene of SEQ ID NO: 1 was grown in LB medium containing 30 μg/ml of kanamycin at 37 °C until the absorbance at 600 nm reached about 0.7, was added isopropyl-β-D-thiogalactopyranoside at a final concentration of 1 mM, then cells were cultured at 37°C for 4 hours. Subsequently, centrifugation was performed at 4800 rpm for 10 minutes, then cells were collected. The resulting cell pellet was suspended in phosphate buffered saline and centrifuged at 4800 rpm for 10 minutes, then the cells were washed.
[154] Cells were suspended in phosphate-buffered saline and then disrupted using ultrasound on ice. The resulting lysate from ultrasonicated Escherichia coli was subjected to centrifugation at 6000 rpm for 20 minutes and then the resulting supernatant was considered as a soluble fraction and the precipitate was considered as an insoluble fraction.
[155] The soluble fraction was added to a nickel chelate column fitted according to a conventional method (carrier: “Chelating Sepharose®Fast Flow” resin (GE Healthcare), 5 ml column capacity, and an equilibration buffer : 50 mM hydrochloride buffer (pH 8.0)). Non-adsorbed fractions were washed with 50 mM hydrochloride buffer (pH 8.0) in an amount of 10 times the column capacity and 20 mM phosphate buffer (pH 8.0) containing 20 mM imidazole. Immediately after washing, 6 beds were eluted with 20 mM phosphate buffer (pH 8.0) containing 100 mM imidazole. Elution of the protein of interest was confirmed by staining with Coomassie stain on the elution fraction with 20 mM phosphate buffer (pH 8.0) containing 100 mM imidazole and then the elution fraction was added to a column of strong anion exchange (carrier: “Q Sepharose®Fast Flow” resin (GE Healthcare), 5 ml column capacity, and 20 mM phosphate buffer (pH 8.0) as equilibration buffer). An unadsorbed fraction was washed with 20 mM phosphate buffer (pH 7.0) in an amount of 10 times the column capacity and 20 mM phosphate buffer (pH 7.0) containing 200 mM sodium chloride. Immediately after washing, 5 beds were eluted with 20 mM phosphate buffer (pH 7.0) containing 400 mM sodium chloride, thus the purified fraction of the protein having the amino acid sequence represented by SEQ ID NO: 2 was obtained.
[156] 200 μL of each purified sample obtained by the method described above was distributed in 1 ml of reaction buffer (20 mM Tris-Hcl, 50 mM NaCl, 2 mM CaCl2, pH 7.4), followed by addition 2 μL of enterokinase (Novagen). Thereafter, the resultant was left to stand overnight at room temperature so that the His-tag was cleaved, and then purification was performed using an enterokinase cleavage capture capture kit "Enterokinase Cleavage Capture Kit" (Novagen), according to the manufacturer's protocols. Then, 1.2 ml of purified sample obtained by the method described above were subjected to buffer replacement by physiological phosphate buffer (Nissui Pharmaceutical Co., Ltd.), using OMEGA NANOSEP 10K ultrafiltration (PALL). Additionally, sterile filtration was performed using an HT Tuffryn Acrodisc 0.22μm (PALL), then the resultant was used in the next experiment. EXAMPLE 3 PREPARATION OF CHICKEN MONOCLONAL ANTIBODY AGAINST CAPRIN-1
[157] 300 μg of the protein antigen (human CAPRIN-1) shown by SEQ ID NO: 2 and prepared in Example 2 was mixed with an equivalent amount of Freund's complete adjuvant then used as an antigen solution for a chicken. Antigen solution was administered intraperitoneally to 7-week-old chickens, then administration was performed 7 times every 4 weeks, and thus immunization was completed. Each spleen was removed on day 4 after the final immunization, and placed between two sterilized glass slides and then crushed. The resulting product was washed with PBS (-) (Nissui) and then centrifuged at 1500 rpm for 10 minutes to remove the supernatant. This procedure was repeated 3 times so that splenocytes were obtained. The splenocytes thus obtained and the light chain deficient chicken myeloma cells were mixed in a ratio of 5:1. The chicken myeloma cells used were established from a chicken by transformation using an avian reticuloendotheliosis virus. The PEG solution prepared by mixing 200 µL of IMDM medium containing 10% FBS heated to 37°C and 800 µL of PEG1500 (Boehringer) was added to the mixture, allowed to stand for 5 minutes for cell fusion, and then submitted to centrifugation at 1700 rpm for 5 minutes. After removing the supernatant, cells were suspended in 300 ml of IMDM medium containing 10% FBS, supplemented with a HAT solution (Gibco) (2% in equivalents) (selective HAT medium), then the cell suspension was plated in thirty 96-well plates (Nunc) at 100 µL per well. Cells were cultured for 7 days at 37°C under 5% CO2 conditions, so that hybridomas prepared by fusion of splenocytes and myeloma cells were obtained.
[158] Hybridomas were selected using an antibody binding affinity tag produced by the prepared hybridomas for the CAPRIN-1 protein. The CAPRIN-1 protein solution (1 µg/ml) prepared in Example 2 was added to a 96-well plate with 100 µl per well and then left to stand at 4°C for 18 hours. Each well was washed 3 times with PBS-T, 400 µL of a 0.5% solution of Bovine Serum Albumin (BSA) (Sigma) was added to each well, then the plate was allowed to stand at room temperature for 3 hours. The solution was removed and then the wells were washed three times with 400 µL of PBS-T per well. The culture supernatant from the hybridomas obtained above was added to a volume of 100 µl per well and then the plates were allowed to stand at room temperature for 2 hours. After washing each well three times with PBS-T, an HRP-labeled anti-chicken IgG IgY antibody (Sigma) diluted 5000 times with PBS was added to 100 µL per well and the resultant was allowed to stand at temperature environment for 1 hour. After washing the well three times with PBS-T, 100 µL of a TMB substrate solution (Thermo) was added to each well and then the plate was left to stand for 15 to 30 minutes for the staining reaction. After color development, 100 μL of 1N sulfuric acid was added to each well to stop the reaction, then absorbances at 450 nm and 595 nm were measured using an absorption spectrometer. As a result, hybridomas that produce antibodies with high absorbance values were selected.
[159] The hybridomas thus selected were added to a 96-well plate at 0.5 cells per well and then cultured. After 1 week, hybridomas that formed isolated colonies in the wells were observed. These cells in the culture wells were cultivated for a longer time, then the hybridomas were selected using as a marker the binding affinity of the antibodies produced by the cloned hybridomas with the CAPRIN-1 protein. The CAPRIN-1 protein solution (1 µg/ml) prepared in Example 2 was added to a 96-well plate, 100 µl per well, and then left to stand at 4°C for 18 hours. Each well was washed three times with PBS-T, 400 µL of a 0.5% BSA solution was added to each well, then the plate was left to stand at room temperature for 3 hours. The solution was removed and then the wells were washed three times with 400 µL of PBS-T per well. 100 µl of each culture supernatant from the hybridomas obtained above was added per well, and then the plate was left to stand at room temperature for 2 hours. After washing each well three times with PBS-T, 100 μL of a HRP-labeled anti-chicken IgG antibody (Sigma) diluted 5,000 times with PBS was added per well, then the plate was allowed to rest at temperature environment for 1 hour. After washing the well three times with PBS-T, 100 µL of a TMB substrate solution (Thermo) was added to each well and then the plate was left to stand for 15 to 30 minutes for the staining reaction. After color development, 100 μL of 1N sulfuric acid was added to each well to stop the reaction, then absorbances at 450 nm and 595 nm were measured using an absorption spectrometer. As a result, several hybridoma cell lines producing monoclonal antibodies reactive against the CAPRIN-1 protein were obtained.
[160] Next, from these monoclonal antibodies, antibodies reactive with the cell surfaces of breast cancer cells expressing CAPRIN-1 were selected. Specifically, 5 x 105 cells of the human breast cancer cell line MDA-MB-231V were subjected to centrifugation in a 1.5 ml microcentrifuge tube, and 100 μL of the culture supernatant from each of the above hybridomas was added to the tube, then the tube was left to stand on ice for 1 hour. After washing with PBS, a FITC-labeled goat anti-chicken IgG (H + L) antibody (SouthernBiotech) diluted 30 times with PBS containing 0.1% FBS was added, then the resulting solution was allowed to stand. on ice for 1 hour. After washing with PBS, fluorescence intensity was measured using a FACScalibur (Becton, Dickinson & Company). Meanwhile, similar procedures to the above were performed for the hybridoma culture medium, so that a control sample was obtained. As a result, a monoclonal antibody was selected (monoclonal antibody #1) that exhibited stronger fluorescence intensity than the control, ie, that reacted with the cell surfaces of breast cancer cells expressing CAPRIN-1. EXAMPLE 4 CHARACTERIZATION OF THE SELECTED ANTIBODY (1) CLONING OF GENES FROM THE VARIABLE REGIONS OF ANTI-CAPRIN-1 MONOCLONAL ANTIBODY
[161] The mRNA was extracted from a chicken-derived hybridoma cell line that produces monoclonal antibodies (selected in example 3) reactive with the surfaces of breast cancer cells expressing CAPRIN-1. An RT-PCR method using specific primers for chicken FR1 derived sequence and chicken FR4 derived sequence was performed for them, and the antibody heavy chain (VH) and light chain (VL) variable region genes They were obtained. The mRNA was also extracted from two mouse-derived hybridoma cell lines that produce monoclonal antibodies reactive with the surfaces of breast cancer cells expressing CAPRIN-1. An RT-PCR method using specific primers for mouse FR1-derived sequence and mouse FR4-derived sequence was performed for them, and the heavy chain (VH) and light chain (VL) variable region genes of each one of the antibodies was obtained. For sequence determination, these genes were cloned into a pCR2.1 vector (Invitrogen). (1)-1 RT-PCR
[162] After extracting total RNA from 106 cells of each hybridoma cell line using a "High Pure RNA Isolation Kit" (Roche), cDNA was synthesized using the "PrimeScriptII 1st strand cDNA Synthesis Kit" synthesis kit (Takara). These procedures were performed according to protocols attached to each kit.
[163] The chicken antibody heavy chain variable region gene and the chicken light chain variable region gene, and the mouse antibody heavy chain variable region gene and the mouse light chain variable region gene. mouse antibodies were each amplified by a PCR method according to a conventional method, using the synthesized cDNA as a template and the DNA polymerase “KOD-Plus DNA-Polymerase” (TOYOBO).
[164] To obtain the chicken antibody VH region gene, a primer specific for chicken heavy chain FR1 sequence and a primer specific for chicken heavy chain FR4 sequence FR4 were used. from the VL region, a primer specific for the FR1 sequence of the chicken light chain and a primer specific for the FR4 sequence of the FR4 chicken light chain were used. The mouse antibody VH and VL region genes were obtained in a similar manner as described above. Specifically, a primer specific for the mouse heavy chain FR1 sequence, a specific primer for the mouse heavy chain FR4 sequence, a specific primer for the mouse light chain FR1 sequence, and a specific primer for the mouse light chain FR4 sequence were used.
[165] The PCR products thus obtained were subjected to agarose gel electrophoresis, and the DNA bands from the VH region and from the VL region were excised. DNA fragments were purified using a QIAquick Gel purification kit (QIAGEN) according to the manufacturer's protocol. Purified DNA was cloned into pCR2.1 vector using the TA cloning kit (Invitrogen). The ligated vector was transformed into competent DH5 cells (TOYOBO) according to a standard method. 10 clones from each transformant were cultured overnight in medium 100 µg/ml ampicillin) at 37°C, then plasmid DNA was purified using a purification kit “Qiaspin Miniprep kit” (QIAGEN). (1)-2 DETERMINATION OF THE SEQUENCE
[166] The gene sequences of the VH region and the VL region in each plasmid obtained above were analyzed with a forward primer M13 (SEQ ID NO: 47) and a reverse primer (reverse) M13 (SEQ ID NO: 48) on a fluorescence sequencer (DNA Sequencer 3130XL; ABI) using a “Big Dye Terminator Cycle Sequencing Kit” Ver3.1 (ABI) sequencing kit according to the manufacturer's protocols. As a result, each gene sequence was determined. Sequences were identical among the 10 clones.
[167] The sequence obtained from the gene encoding the heavy chain variable region of the chicken-derived monoclonal antibody is represented by SEQ ID NO: 49 and the derived amino acid sequence is represented by SEQ ID NO: 42, and the obtained sequence of the light chain variable region coding gene is represented by SEQ ID NO: 50 and the amino acid sequence derived therefrom is represented by SEQ ID NO: 46.
[168] Specifically, it was disclosed that monoclonal antibody #1 comprises the heavy chain variable region of SEQ ID NO: 42 and the light chain variable region of SEQ ID NO: 46, wherein the CDR1, CDR2 and CDR3 in the region heavy chain variable consist of the amino acid sequences of SEQ ID NOS: 39, 40, and 41, respectively, and the CDR1, CDR2 and CDR3 of the light chain variable region consist of the amino acid sequences of SEQ ID NOS: 43, 44, and 45, respectively. (2) PREPARATION OF HUMAN-CHICKEN CHIMERIC RECOMBINANT ANTIBODY AND MOUSE-CHICKEN CHIMERIC ANTIBODY
[169] A heavy chain variable region gene amplification fragment (SEQ ID NO: 42) of the chicken monoclonal antibody #1 obtained in item (1) above, was treated at both ends with restriction enzymes and then purified. The resulting fragment was inserted into a pcDNA4/myc-His vector (Invitrogen) according to a conventional method, in which a leader sequence derived from chicken antibody comprising SEQ ID NO: 51 and a human IgG1 H chain constant region comprising SEQ ID NO : 52 had already been introduced. In addition, a chicken monoclonal antibody #1 light chain variable region gene amplification fragment (SEQ ID NO: 46) was treated at both ends with the restriction enzymes and then purified. The resulting fragment was inserted into a pcDNA3.1/myc-His vector (Invitrogen) according to a conventional method, in which a chicken antibody-derived leader sequence comprising SEQ ID NO: 51 and a constant region of the L chain of Human IgG1 comprising SEQ ID NO:53 had already been introduced.
[170] Next, the above recombinant vector into which the heavy chain variable region (SEQ ID NO: 42) of the chicken monoclonal antibody #1 has been inserted, and the above recombinant vector into which the light chain variable region ( SEQ ID NO: 46) of monoclonal antibody #1 was inserted, were introduced into CHO-K1 cells (obtained from the RIKEN Cell Bank). Specifically, 2 x 105 CHO-K1 cells cultured in 1 ml of Ham's F12 medium (Invitrogen) containing 10% FBS per well of a 12-well culture plate were washed with PBS(-). 1 ml of Ham's F12 medium containing 10% FBS was added per well and then a mixture of 250 ng of each of the above vectors dissolved in 30 µl of OptiMEM (Invitrogen) and 30 µl of a Polyfect transfection reagent (QIAGEN) were added to each well. CHO-K1 cells into which the above recombinant vector had been introduced were cultured in Ham's F12 medium containing 10% FBS, supplemented with 200 µg/ml Zeocin (Invitrogen) and 200 µg/ml Geneticin (Roche). CHO-K1 cells into which the above recombinant vector was introduced were plated into 96-well plates at a density of 0.5 cells per well. In this way, a cell line capable of stably producing a chimeric human-chicken antibody #1 (also referred to as #1) that has the variable region of the chicken monoclonal antibody #1 was prepared. The cell line thus prepared was grown in a 150 cm2 flask containing 30 ml of OptiCHO serum free medium (Invitrogen) at 5 x 105 cells/ml for 5 days. Then a culture supernatant containing #1 was obtained.
[171] With a method similar to that described above, an amplification fragment of the heavy chain variable region gene (SEQ ID NO: 42) from chicken monoclonal antibody #1, was treated at both ends with restriction enzymes and then purified. The resulting fragment was inserted according to a conventional method into a pcDNA4/myc-His vector (Invitrogen) in which the chicken antibody-derived leader sequence and the human IgG1 L chain constant region had already been inserted. In addition, a light chain variable region gene amplification fragment (SEQ ID NO: 46) from chicken monoclonal antibody #1 was treated at both ends with restriction enzymes and then purified. The resulting fragment was then inserted according to a conventional method into a pcDNA3.1/myc-His vector (Invitrogenno in which the chicken antibody-derived leader sequence and the human IgG1 L chain constant region had already been inserted. The resultant was introduced into CHO-K1 cells in a similar manner as described above, and thus a cell line was prepared that stably produces a mouse-chimeric antibody #1 comprising the variable region of the chicken monoclonal antibody #1. Cells were cultured at a density of 5 x 105 cells/ml, using a 150 cm2 and 30 ml flask and serum-free OptiCHO medium (Invitrogen) for 5 days, so that a culture supernatant containing the mouse-chicken chimeric antibody #1 has been obtained. (3) EXPRESSION OF CAPRIN-1 ON THE SURFACE OF SEVERAL CANCER CELLS USING ANTI-CAPRIN-1 ANTIBODY #1
[172] Next, 7 breast cancer cell lines (MDA-MB-157, T47D, MRK-nu-1, MDA-MB-231V, BT20, SK-BR-3, and DA-MB-231T) in which a gene expressing CAPRIN-1 was observed, and three other breast cancer cell lines (MDA-MB-231c, MCF-7 and ZR75-1), 5 glioma cell lines (T98G, SNB19, U251, U87MG, and U373), 4 renal cancer cell lines (Caki-1, Caki-2, A498 and ACHN), 2 gastric cancer cell lines (MNK28 and MNK45), 5 colorectal cancer cell lines (HT29, LoVo, Caco2, SW480 and HCT116), 3 lung cancer cell lines (A549, QG56 and PC8), 4 leukemia cell lines (AML5, Namalwa, BDCM, RPI1788), one lymphoma cell line (Ramos) , a cervical cancer cell line (SW756), a bladder cancer cell line (T24), and an esophageal cancer cell line (KYSE180) were examined for CAPRIN-1 protein expression on the cell surfaces of each cell line cells using CHO-K1 cell culture supernatants containing antibody #1 obtained in item (2) above. 106 cells from each cell line were centrifuged in a 1.5 ml microcentrifuge tube. Each CHO-K1 cell culture supernatant (100 µL) containing #1 obtained in item (2) above was added and then incubated on ice for 1 hour. After washing with PBS, a FITC-labeled goat anti-human IgG (H+L) antibody (SouthernBiotech) and a FITC-labeled anti-mouse IgG (H+L) antibody (Invitrogen) diluted 500-fold with PBS containing 0.1% FBS was added, then the resulting solution was left to stand on ice for 1 hour. After washing with PBS, fluorescence intensity was measured using a FACS Calibur (Becton, Dickinson & Company). Meanwhile, procedures similar to those described above were performed using a CHO-K1 cell culture supernatant in which no antibody gene and medium for hybridoma culture were introduced, so that a negative control sample was prepared. As a result, cells to which antibody #1 was added exhibited 20% stronger fluorescence intensity compared to the control. Specifically, the fluorescence intensity increased by 4900% for SK-BR-3 and 5,000% for MDA-MB-231V. With these results it was revealed that the CAPRIN-1 protein was expressed on the cell membrane surfaces of the above human cancer cell lines. The percentage increase in fluorescence intensity above was expressed as a percentage of the increase in mean fluorescence intensity (MFI level) in each cell type and was calculated by the following formula.
[173] Percentage increase in mean fluorescence intensity (percentage increase in fluorescence intensity) (%) = ((MFI level in cells that reacted with human anti-CAPRIN-1 antibody) - (Control MFI level)) / (MFI level of the control) x 100. (4) ANTITUMOR EFFECTS (ADCCACTIVITY) OF THE ANTI-CAPRIN-1 ANTIBODY #1 AGAINST CANCER CELLS
[174] The anti-CAPRIN-1 antibody #1 was then evaluated for its cellular cytotoxicity (ADCC activity) against cancer cells. Each #1-producing cell culture supernatant obtained in item (2) above was purified using a "Hitrap ProteinA Sepharose FF" column (GE Healthcare), buffer exchanged with PBS(-), and then filtered with a 0.22 µm filter (Millipore). The resultants were used as antibodies for measuring activity. 106 cells of the human breast cancer cell line MDA-MB-157 were collected in a 50 ml centrifuge tube, 100 μCi of chromium-51 was added, and then incubated at 37 °C for 2 hours . Subsequently, the resulting product was washed three times with RPMI 1640 medium containing 10% FBS. Cells were added to a 96-well V-bottom plate at a density of 5 x 103 cells per well for use as target cells. The purified antibodies above were added to the cells at a final concentration of 1 µg/ml. 2.5 x 105 lymphocyte cells, separated from human peripheral blood according to a conventional method, were added and then cultured under conditions of 37°C and 5% CO2 for 4 hours. After culture, the amount of chromium-51 released from damaged cancer cells in a culture supernatant was measured, and the ADCC activity of each anti-CAPRIN-1 antibody against the cancer cells was calculated. As negative control samples, a sample prepared by adding PBS instead of anti-CAPRIN-1 antibodies and a sample prepared by adding an isotypic control antibody instead of anti-CAPRIN-1 antibodies were used. antibody #1 exhibited greater than 30% or greater cytotoxic activity against the MDA-MB-157 lineage (see Fig. 2). In contrast, the activity of the negative control sample prepared by the addition of PBS and the activity in the negative control sample prepared by the addition of isotypic control antibody were 1.1% and 2.0%, respectively. Similarly, antibody #1 was evaluated for ADCC activity against other cancer cells, including glioma cell lines T98G and U373, lung cancer cell lines A549 and QG56, kidney cancer cell lines Caki-1 and ACHN, cervical cancer cell line SW756, bladder cancer cell line T24, esophageal cancer cell line KYSE180, gastric cancer cell line MKN28 and MNK45, colorectal cancer cell line SW480, esophageal cancer cell line AML5 leukemia cells, Ramos lymphoma cell line. As a result, antibody #1 exhibited 16.4% activity against T98G (1.2% in case of isotypic control), 23.1% against U373 (3.2% in case of isotypic control), 36.1% against A549 (3.0% for isotypic control), 33.5% against QG56 (0.5% for isotypic control), 28.3% against Caki-1 (2.6% for isotypic control ), 25.1% against ACHN (1.6% for isotypic control), 27.9% against SW756 (2.2% for isotypic control), 25.8% against T24 (2.0% for in the case of the negative control), 26.7% against KYSE180 (3.0% in the case of the isotypic control), 21.5% against MNK28 (1.9% in the case of the isotypic control), 23.0% against MNK45 (3 .0% for isotypic control), 24.0% against SW480 (1.8% for isotypic control), 8.3% against AML5 (1.8% for isotypic control), and 8.0 % against Ramos (2.2% in the case of isotypic control). It was demonstrated by the above results that the obtained anti-CAPRIN-1 antibody #1 causes damage to various human cancer cells expressing CAPRIN-1. (5) ANTITUMOR EFFECTS (CDC ACTIVITY) OF ANTI-CAPRIN-1 ANTIBODY #1 AGAINST CANCER CELLS
[175] Next, the anti-CAPRIN-1 antibody #1 was evaluated for cytotoxic activity (CDC activity) against cancer cells. Blood collected from a rabbit was added to an Eppendorf tube and allowed to stand at room temperature for 60 minutes, then subjected to 5 minutes of centrifugation at 3000 rpm. Thus, serum for measuring CDC activity was prepared. 106 MDA-MB-213V human breast cancer cells were collected in a 50 ml centrifuge tube, 100 μCi of chromium-51 was added, and then incubated at 37 °C for 2 hours. The resulting product was washed three times with RPMI 1640 medium containing 10% FBS. Subsequently, cells were suspended in RPMI medium containing the rabbit serum prepared above (50%) and then cells were added to a 96-well V-bottom plate at a density of 5 x 103 cells per well. The antibody #1 obtained in item (5) above was added to the cells at a final concentration of 1 µg/ml and then the cells were cultured for 4 hours at 37°C under 5% CO 2 conditions. After culture, the amount of chromium-51 released from damaged tumor cells in a culture supernatant was measured, and then the CDC activity against MDA-MB-213V cells was calculated. As a result, antibody #1 exhibited 25% or more CDC activity. Therefore, it was revealed that antibody #1 can damage cancer cells expressing CAPRIN-1 also through CDC activity. EXAMPLE 5 IN VIVO ANTITUMOR EFFECTS OF ANTI-CAPRIN-1 ANTIBODY #1 IN MICE
[176] Next, the obtained anti-CAPRIN-1 antibody #1 was evaluated for its anti-tumor effects in vivo in tumor-grafted mice. The antibodies used herein were prepared by column purification of the culture supernatant from each #1 producing cell in the same manner as described above.
[177] The antitumor effects of antibody #1 were examined using tumor-bearing mice into which a mouse-derived cancer cell line expressing CAPRIN-1 was transplanted. 4T1 cells (purchased from ATCC) were transplanted subcutaneously into the dorsal region of 20 Balb/c mice (SLC Japan Inc.) at a density of 5x105 cells per mouse. The cancers were allowed to grow to a size of about 5 mm in diameter. Antibody #1 was administered intraperitoneally to 10 mice out of 30 tumor-bearing mice, in an amount of 200 μg (in 200 μL) per mouse. Subsequently, the same amount of antibody was administered intraperitoneally to each tumor-bearing mouse a total of 3 times within 2 days. Cancer sizes were measured every day and antitumor effects were examined through observation. Meanwhile, as a control group, PBS (-) was administered instead of antibodies to the remaining 10 tumor-bearing mice. As a result of the observation of antitumor effects, in the test group to which anti-CAPRIN-1 antibody #1 was administered, the cancers were considered to have regressed to about 55% on day 4, about 32% on day 6, about of 7% on day 8, and the cancers were observed to regress almost completely before days 10 to 14, so the tumor volume at the start of antibody administration was designated to be 100% (see Fig. 3). In the control group given PBS(-), tumor size increased to about 170%, 270%, 440%, and 670% on days 4, 6, 8, and 11, respectively (see Fig. 3). It was shown by the results that the obtained antibody #1 exhibits strong antitumor effect in vivo against cancer cells expressing CAPRIN-1. Tumor (cancer) size was calculated as a volume using the formula: major axis length x minor axis length x minor axis length x 0.5. INDUSTRIAL APPLICABILITY
[178] The antibodies of the present invention are useful to treat and/or prevent cancer.
[179] All publications, patents, and patent applications cited herein are fully incorporated herein by reference. FREE TEXT SEQUENCE LISTING
[180] SEQ ID NOS: 31-38, 47, and 48: primers.

权利要求:
Claims (9)
[0001]
1. ANTIBODY, characterized in that it comprises a heavy chain variable region comprising complementarity determining regions (CDRs) 1 to 3 represented by SEQ ID NOS: 39, 40, and 41, respectively, and a light chain variable region comprising CDRs 1 to 3 represented by SEQ ID NOS: 43, 44, and 45, respectively, and have immunological reactivity with a CAPRIN-1 protein.
[0002]
2. ANTIBODY, according to claim 1, characterized in that it is a human antibody, humanized antibody, chimeric antibody, single-chain antibody, or bispecific antibody.
[0003]
3. PHARMACEUTICAL COMPOSITION, characterized in that it comprises an antibody, as defined in any one of claims 1 to 2, or a fragment thereof, as an active ingredient.
[0004]
4. COMPOSITION according to claim 3, characterized in that it additionally comprises an antitumor agent.
[0005]
5. PHARMACEUTICAL COMBINATION, characterized in that it comprises the pharmaceutical composition, as defined in any one of claims 3 to 4, and a pharmaceutical composition containing an antitumor agent.
[0006]
6. USE OF AN ANTIBODY, as defined in any one of claims 1 to 2, characterized in that it is for the manufacture of a drug to treat and/or prevent cancer.
[0007]
7. USE OF A PHARMACEUTICAL COMPOSITION, as defined in any one of claims 3 to 4, characterized in that it is for the manufacture of a drug to treat and/or prevent cancer.
[0008]
8. USE OF A PHARMACEUTICAL COMBINATION, as defined in claim 5, characterized in that it is for the manufacture of a drug to treat and/or prevent cancer.
[0009]
9. USE according to any one of claims 6 to 8, characterized in that the cancer is breast cancer, brain tumor, leukemia, lymphoma, lung cancer, mast cell tumor, kidney cancer, cervical cancer, esophageal cancer, gastric cancer , bladder cancer, or colorectal cancer.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US20210188998A1|2021-06-24|Pharmaceutical composition for treatment and prevention of cancers

---

US9416191B2|2016-08-16|Pharmaceutical composition for treatment and/or prevention of cancer

---

BR112012019098B1|2021-07-06|antibody, pharmaceutical composition, pharmaceutical combination and uses of an antibody, a pharmaceutical composition and a pharmaceutical combination

---

US9115200B2|2015-08-25|Pharmaceutical composition for treating cancer using a monoclonal antibody having immunological reactivity with CAPRIN-1

---

US8911740B2|2014-12-16|Pharmaceutical composition for treating and/or preventing cancer

---

US8937160B2|2015-01-20|Pharmaceutical composition for treating and/or preventing cancer

---

BR112012018948B1|2021-12-14|PHARMACEUTICAL COMPOSITIONS, ANTIBODIES, PHARMACEUTICAL COMBINATION, USES OF A PHARMACEUTICAL COMPOSITION, USE OF AN ANTIBODY AND USE OF A PHARMACEUTICAL COMBINATION

同族专利:

---

公开号 | 公开日

---

BR112012019098A2|2018-03-27|

---

CN102822199B|2014-10-15|

---

DK2532680T3|2015-07-20|

---

AU2011211684A1|2012-08-23|

---

KR101758117B1|2017-07-14|

---

JPWO2011096519A1|2013-06-13|

---

EP2532680A4|2013-11-27|

---

JP5845899B2|2016-01-20|

---

US8709418B2|2014-04-29|

---

WO2011096519A1|2011-08-11|

---

KR20120125327A|2012-11-14|

---

ES2543174T3|2015-08-17|

---

EP2532680A9|2014-12-17|

---

RU2567657C2|2015-11-10|

---

PT2532680E|2015-09-14|

---

HUE025678T2|2016-04-28|

---

PL2532680T3|2015-10-30|

---

RU2012137505A|2014-03-10|

---

CN102822199A|2012-12-12|

---

AU2011211684B2|2014-09-25|

---

EP2532680B1|2015-04-29|

---

EP2532680A1|2012-12-12|

---

CA2788547C|2018-06-05|

---

US20120321641A1|2012-12-20|

---

MX2012008996A|2012-09-07|

---

BR112012019098B8|2021-08-17|

---

CA2788547A1|2011-08-11|

---

MX340017B|2016-06-22|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

GB8607679D0|1986-03-27|1986-04-30|Winter G P|Recombinant dna product|

---

US5994524A|1994-07-13|1999-11-30|Chugai Seiyaku Kabushiki Kaisha|Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same|

---

US5698396A|1995-06-07|1997-12-16|Ludwig Institute For Cancer Research|Method for identifying auto-immunoreactive substances from a subject|

---

FR2761994B1|1997-04-11|1999-06-18|Centre Nat Rech Scient|PREPARATION OF MEMBRANE RECEPTORS FROM EXTRACELLULAR BACULOVIRUSES|

---

CA2325346A1|1998-04-03|1999-10-14|Chugai Seiyaku Kabushiki Kaisha|Humanized antibody against human tissue factor and process for constructing humanized antibody|

---

WO2002083070A2|2001-04-10|2002-10-24|Corixa Corporation|Compounds for immunotherapy and diagnosis of colon cancer and methods for their use|

---

US6969518B2|1998-12-28|2005-11-29|Corixa Corporation|Compositions and methods for the therapy and diagnosis of breast cancer|

---

US6335170B1|1999-02-22|2002-01-01|Torben F. Orntoft|Gene expression in bladder tumors|

---

US6444425B1|1999-04-02|2002-09-03|Corixa Corporation|Compounds for therapy and diagnosis of lung cancer and methods for their use|

---

US20030118599A1|1999-04-02|2003-06-26|Corixa Corporation|Compositions and methods for the therapy and diagnosis of lung cancer|

---

AU4185100A|1999-04-02|2000-10-23|Corixa Corporation|Compounds for therapy and diagnosis of lung cancer and methods for their use|

---

US6949245B1|1999-06-25|2005-09-27|Genentech, Inc.|Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies|

---

AU1438001A|1999-10-29|2001-05-14|Human Genome Sciences, Inc.|27 human secreted proteins|

---

JP2004526401A|2000-03-29|2004-09-02|コリクサコーポレイション|Compositions and methods for treatment and diagnosis of lung cancer|

---

WO2002092001A2|2001-05-11|2002-11-21|Corixa Corporation|Compositions and methods for the therapy and diagnosis of lung cancer|

---

JP3523245B1|2000-11-30|2004-04-26|メダレックス，インコーポレーテッド|Transgenic chromosome-introduced rodents for the production of human antibodies|

---

US7919467B2|2000-12-04|2011-04-05|Immunotope, Inc.|Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer|

---

US20040029114A1|2001-01-24|2004-02-12|Eos Technology, Inc.|Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer|

---

AU2002311787A1|2001-03-28|2002-10-15|Zycos Inc.|Translational profiling|

---

JP4115281B2|2001-05-11|2008-07-09|キリンファーマ株式会社|Human artificial chromosome containing human antibody λ light chain gene, and non-human animal containing the human artificial chromosome capable of offspring transmission|

---

US20030190640A1|2001-05-31|2003-10-09|Mary Faris|Genes expressed in prostate cancer|

---

US20040142325A1|2001-09-14|2004-07-22|Liat Mintz|Methods and systems for annotating biomolecular sequences|

---

US20050003390A1|2002-05-17|2005-01-06|Axenovich Sergey A.|Targets for controlling cellular growth and for diagnostic methods|

---

US20060121029A1|2002-08-30|2006-06-08|Hiroshi Shiku|Method and composition for regulating the activity of regulatory t cells|

---

EP1572116A4|2002-11-26|2007-12-12|Genentech Inc|Compositions and methods for the treatment of immune related diseases|

---

WO2004076682A2|2003-02-26|2004-09-10|Surromed, Inc.|Targets for controlling cellular growth and for diagnostic methods|

---

US20050202451A1|2003-04-29|2005-09-15|Burczynski Michael E.|Methods and apparatuses for diagnosing AML and MDS|

---

CA2528669A1|2003-06-09|2005-01-20|The Regents Of The University Of Michigan|Compositions and methods for treating and diagnosing cancer|

---

US20070048738A1|2003-07-14|2007-03-01|Mayo Foundation For Medical Education And Research|Methods and compositions for diagnosis, staging and prognosis of prostate cancer|

---

US20050032113A1|2003-07-17|2005-02-10|Mitsubishi Pharma Corporation|Membrane protein library for proteome analysis and method for preparing same|

---

RU2429245C2|2004-03-30|2011-09-20|Глаксо Груп Лимитед|Immunoglobulins|

---

WO2005100998A2|2004-04-16|2005-10-27|Europroteome Ag|Membrane markers for use in cancer diagnosis and therapy|

---

DE102004026135A1|2004-05-25|2006-01-05|Immatics Biotechnologies Gmbh|Tumor-associated peptides binding to MHC molecules|

---

WO2006002378A2|2004-06-23|2006-01-05|Avalon Pharmaceuticals|Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods|

---

RU2297241C2|2004-11-22|2007-04-20|Государственное учреждение Российский научный центр рентгенорадиологии Министерства здравоохранения и социального развития|Chimeric protein for malignant lymphoma treatment|

---

MX2007008768A|2005-01-21|2007-10-19|Genentech Inc|Fixed dosing of her antibodies.|

---

AU2006214105A1|2005-02-18|2006-08-24|Children's Medical Center Corporation|Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin|

---

NZ560976A|2005-03-11|2011-06-30|Univ Johns Hopkins|Biomarkers for ovarian cancer and endometrial cancer: hepcidin|

---

JP2006316040A|2005-05-13|2006-11-24|Genentech Inc|Herceptin adjuvant treatment|

---

US8014957B2|2005-12-15|2011-09-06|Fred Hutchinson Cancer Research Center|Genes associated with progression and response in chronic myeloid leukemia and uses thereof|

---

EP1991701A4|2006-02-14|2010-03-17|Dana Farber Cancer Inst Inc|Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer|

---

WO2008073162A2|2006-08-17|2008-06-19|Cell Signaling Technology, Inc.|Lysine acetylation sites|

---

US20080107668A1|2006-08-30|2008-05-08|Immunotope, Inc.|Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer|

---

US7615349B2|2006-09-07|2009-11-10|H. Lee Moffitt Cancer Center And Research Institute, Inc.|Melanoma gene signature|

---

WO2008059252A2|2006-11-15|2008-05-22|Oxford Biomedica Limited|Methods and composition fro t cell receptors which recognize 5t4 antigen|

---

JP2010023452A|2008-07-24|2010-02-04|Seiko Epson Corp|Printer and data communication method|

---

DK2837383T3|2008-08-05|2017-03-20|Toray Industries|Immunity Inducing Agent|

---

MX2011001445A|2008-08-05|2011-04-05|Toray Industries|Cancer detection method.|

---

PT2322221E|2008-08-05|2014-09-19|Toray Industries|Pharmaceutical composition for treatment and prevention of cancer|

---

PT2532365T|2010-02-04|2016-07-28|Toray Industries|Pharmaceutical composition for treatment and/or prevention of cancer|

---

EP2532364B1|2010-02-04|2016-05-04|Toray Industries, Inc.|Pharmaceutical composition comprising anti caprin-1 antibodies for treating and/or preventing cancer|

---

HUE040012T2|2010-02-04|2019-02-28|Toray Industries|Pharmaceutical agent for treatment and/or prevention of cancer|

---

US8828398B2|2010-02-04|2014-09-09|Toray Industries, Inc.|Pharmaceutical composition for treating and/or preventing cancer|

---

JP5742713B2|2010-02-04|2015-07-01|東レ株式会社|Pharmaceutical composition for treatment and / or prevention of cancer|

---

RU2630638C2|2011-08-04|2017-09-11|Торэй Индастриз, Инк.|Pharmaceutical composition for pancreatic cancer treatment and/or prevention|

---

HUE033628T2|2011-08-04|2017-12-28|Toray Industries|Method for detecting pancreatic cancer|

---

RU2641260C2|2011-08-04|2018-01-16|Торэй Индастриз, Инк.|Pharmaceutical composition for cancer treatment and prevention|MX2011001445A|2008-08-05|2011-04-05|Toray Industries|Cancer detection method.|

---

PT2322221E|2008-08-05|2014-09-19|Toray Industries|Pharmaceutical composition for treatment and prevention of cancer|

---

HUE040012T2|2010-02-04|2019-02-28|Toray Industries|Pharmaceutical agent for treatment and/or prevention of cancer|

---

EP2532364B1|2010-02-04|2016-05-04|Toray Industries, Inc.|Pharmaceutical composition comprising anti caprin-1 antibodies for treating and/or preventing cancer|

---

US8828398B2|2010-02-04|2014-09-09|Toray Industries, Inc.|Pharmaceutical composition for treating and/or preventing cancer|

---

PT2532365T|2010-02-04|2016-07-28|Toray Industries|Pharmaceutical composition for treatment and/or prevention of cancer|

---

JP5742713B2|2010-02-04|2015-07-01|東レ株式会社|Pharmaceutical composition for treatment and / or prevention of cancer|

---

RU2641260C2|2011-08-04|2018-01-16|Торэй Индастриз, Инк.|Pharmaceutical composition for cancer treatment and prevention|

---

ES2660115T3|2011-08-04|2018-03-20|Toray Industries, Inc.|Pharmaceutical composition for the treatment and / or prevention of cancer|

---

HUE033628T2|2011-08-04|2017-12-28|Toray Industries|Method for detecting pancreatic cancer|

---

MX348581B|2011-08-04|2017-06-20|Toray Industries|Cancer treatment and/or prevention drug composition.|

---

AU2012290954B2|2011-08-04|2017-08-31|Toray Industries, Inc.|Pharmaceutical composition for treatment and/or prophylaxis of cancer|

---

PT2740795T|2011-08-04|2017-01-09|Toray Industries|Cancer treatment and/or prevention drug composition|

---

RU2630638C2|2011-08-04|2017-09-11|Торэй Индастриз, Инк.|Pharmaceutical composition for pancreatic cancer treatment and/or prevention|

---

DK2818482T3|2012-02-21|2019-07-15|Toray Industries|PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT|

---

CN104114582B|2012-02-21|2018-12-21|东丽株式会社|The treatment of cancer and/or prophylactic compositions|

---

JP6187257B2|2012-02-21|2017-08-30|東レ株式会社|Pharmaceutical composition for treatment and / or prevention of cancer|

---

EP2824114B1|2012-02-21|2019-05-22|Toray Industries, Inc.|Pharmaceutical composition for treatment of cancer|

---

HUE036424T2|2012-03-30|2018-07-30|Toray Industries|Pharmaceutical composition for treatment and/or prevention of liver cancer|

---

PT2832366T|2012-03-30|2018-01-25|Toray Industries|Pharmaceutical composition for treatment and/or prevention of gallbladder cancer|

---

TR201902972T4|2012-07-19|2019-03-21|Toray Industries|Method for detecting cancer.|

---

MX358772B|2012-07-19|2018-09-04|Toray Industries|Cancer detection method.|

---

US9862774B2|2013-08-09|2018-01-09|Toray Industries, Inc.|Pharmaceutical composition for treatment and/or prevention of cancer|

---

KR20190026761A|2016-07-07|2019-03-13|더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티|Antibody-adjuvant conjugate|

---

CN109890417A|2016-10-28|2019-06-14|东丽株式会社|The treatment of cancer and/or prophylactic compositions|

---

KR102120223B1|2017-12-08|2020-06-08|세종대학교산학협력단|Medicinal composition for preventing or treating cancers|

---

US20210121562A1|2018-03-30|2021-04-29|Toray Industries, Inc.|Pharmaceutical composition for treatment and/or prevention of cancer|

---

AU2020291014A1|2019-06-13|2022-01-27|Bolt Biotherapeutics, Inc.|Aminobenzazepine compounds, immunoconjugates, and uses thereof|

---

WO2021067242A1|2019-09-30|2021-04-08|Bolt Biotherapeutics, Inc.|Amide-linked, aminobenzazepine immunoconjugates, and uses thereof|

---

TW202128226A|2019-10-25|2021-08-01|美商博特生物治療公司|Thienoazepine immunoconjugates, and uses thereof|

---

WO2021226440A1|2020-05-08|2021-11-11|Bolt Biotherapeutics, Inc.|Elastase-substrate, peptide linker immunoconjugates, and uses thereof|

法律状态:
2018-04-10| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2019-07-09| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |

---

2020-08-04| B07E| Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|

---

2020-09-29| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2021-04-27| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2021-07-06| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/02/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |

---

2021-08-17| B16C| Correction of notification of the grant|Free format text: REF. RPI 2635 DE 06/07/2021 QUANTO AO TITULO. |

优先权:

---

申请号 | 申请日 | 专利标题

---

JP2010-023452|2010-02-04|

---

JP2010023452|2010-02-04|

---

PCT/JP2011/052384|WO2011096519A1|2010-02-04|2011-02-04|Medicinal composition for treating and/or preventing cancer|

---